NovaBay Pharmaceuticals (NBY) 10-K 29 Mar 22 2021 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 24, 2022	Jun. 30, 2021
Document Information [Line Items]
Entity Central Index Key	0001389545
Entity Registrant Name	NOVABAY PHARMACEUTICALS, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Document Transition Report	false
Entity File Number	001-33678
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	68-0454536
Entity Address, Address Line One	2000 Powell Street, Suite 1150
Entity Address, City or Town	Emeryville
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94608
City Area Code	510
Local Phone Number	899-8800
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	NBY
Security Exchange Name	NYSEAMER
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Emerging Growth Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 23,677,038
Entity Common Stock, Shares Outstanding		51,418,364
Auditor Name	WithumSmith+Brown, PC
Auditor Location	San Francisco California
Auditor Firm ID	100

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
ASSETS
Cash and cash equivalents	$ 7,504	$ 11,952
Accounts receivable, net of allowance for doubtful accounts ($0 at December 31, 2021 and December 31, 2020)	1,668	1,106
Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($641 and $236 at December 31, 2021 and December 31, 2020, respectively)	3,220	608
Prepaid expenses and other current assets	778	576
Total current assets	13,170	14,242
Operating lease right-of-use assets	411	436
Property and equipment, net	193	84
Goodwill	4,528	0
Other intangible assets, net	5,200	0
Other assets	476	476
TOTAL ASSETS	23,978	15,238
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable	1,045	302
Accrued liabilities	2,092	2,115
Line of credit	105	0
Operating lease liability	200	416
Total current liabilities	3,442	2,833
Operating lease liabilities-non-current	246	87
Warrant liability	9,558	0
Contingent earnout liability	561	0
Total liabilities	13,807	2,920
Commitments & contingencies (Note 10)
Stockholders' equity:
Preferred stock, $0.01 par value; 5,000 shares authorized; 14 and 0 issued and outstanding at December 31, 2021 and December 31, 2020, respectively	680	0
Common stock, $0.01 par value; 100,000 and 75,000 shares authorized, 47,766 and 41,782 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively	478	418
Additional paid-in capital	150,900	147,963
Accumulated deficit	(141,887)	(136,063)
Total stockholders' equity	10,171	12,318
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 23,978	$ 15,238

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Accounts receivable, allowance for doubtful accounts	$ 0	$ 0
Inventory, allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments	$ 641	$ 236
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares outstanding (in shares)	14,000	0
Preferred stock, shares issued (in shares)	14,000	0
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	75,000,000
Common stock, shares issued (in shares)	47,766,000	41,782,000
Common stock, shares outstanding (in shares)	47,766,000	41,782,000

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Sales:
Total sales, net	$ 8,421	$ 9,934	$ 6,599
Cost of goods sold	2,776	3,970	1,738
Gross profit	5,645	5,964	4,861
Research and development	44	285	184
Sales and marketing	7,223	6,173	8,767
General and administrative	7,240	5,932	5,310
Total operating expenses	14,507	12,390	14,261
Operating loss	(8,862)	(6,426)	(9,400)
Non-cash gain (loss) on changes in fair value of warrant liability	4,615	(5,216)	749
Non-cash gain on changes in fair value of embedded derivative liability	0	3	424
Other (expense) income, net	(1,577)	605	(1,425)
Loss before provision for income taxes	(5,824)	(11,034)	(9,652)
Provision for income taxes	0	(5)	(6)
Net loss and comprehensive loss	(5,824)	(11,039)	(9,658)
Less: Preferred deemed dividend	735	0	800
Less: Retained earnings reduction related to warrants down round feature triggered	0	0	29
Net loss attributable to common stockholders	$ (6,559)	$ (11,039)	$ (10,487)
Net loss per share attributable to common stockholders (basic and diluted) (in dollars per share)	$ (0.15)	$ (0.31)	$ (0.48)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock (basic and diluted) (in shares)	43,657	35,076	21,641
Product [Member]
Sales:
Total sales, net	$ 8,397	$ 9,916	$ 6,556
Product and Service, Other [Member]
Sales:
Total sales, net	$ 24	$ 18	$ 43

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Series A Preferred Stock [Member]Preferred Stock [Member]	Series A Preferred Stock [Member]Common Stock [Member]	Series A Preferred Stock [Member]Additional Paid-in Capital [Member]	Series A Preferred Stock [Member]	Nonemployees [Member]Common Stock [Member]	Nonemployees [Member]Additional Paid-in Capital [Member]	Nonemployees [Member]	Employee [Member]Common Stock [Member]	Employee [Member]Additional Paid-in Capital [Member]	Employee [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2018											0	17,089,000
Balance at Dec. 31, 2018											$ 0	$ 171,000	$ 119,764,000	$ (114,981,000)	$ 4,954,000
Net loss														(9,658,000)	(9,658,000)
Reclassification of warrant liability to equity											$ 0		412,000	(356,000)	56,000
Down round feature adjustment related to warrants													29,000	(29,000)
Issuance of preferred stock and common stock warrants, net of offering costs (in shares)	2,700,000
Issuance of preferred stock and common stock warrants, net of offering costs	$ 584,000
Conversion of preferred stock to common stock (in shares)	(2,700,000)	2,700,000
Conversion of preferred stock to common stock	$ (584,000)														(584,000)
Conversion of preferred stock to common stock		$ 27,000	$ 557,000	$ 584,000
Beneficial conversion feature upon issuance of preferred stock			800,000	800,000
Deemed dividend from beneficial conversion feature of preferred stock			(800,000)	(800,000)
Issuance of common stock in connection with offering, net of offering costs (in shares)												7,467,000
Issuance of common stock in connection with offering, net of offering costs												$ 75,000	3,427,000		3,502,000
Issuance of common stock in connection with exercise of warrants (in shares)												389,000
Issuance of common stock in connection with exercise of warrants												$ 4,000	616,000		620,000
Issuance of RSUs related to employee separation agreement (in shares)												168,000
Issuance of RSUs related to employee separation agreement												$ 2,000	218,000		$ 220,000
Issuance of common stock for option exercises (in shares)												83,000			83,000
Issuance of common stock for option exercises													189,000		$ 189,000
Issuance of RSUs (in shares)					36,000			6,000
Issuance of RSUs						$ 20,000	$ 20,000		$ 10,000	$ 10,000
Stock-based compensation expense related to employee and director stock options													334,000		334,000
Stock-based compensation expense related to non-employee stock options													37,000		37,000
Stock option modification													105,000		105,000
Deemed dividend from beneficial conversion feature of preferred stock			$ 800,000	$ 800,000
Balance (in shares) at Dec. 31, 2019											0	27,938,000
Balance at Dec. 31, 2019											$ 0	$ 279,000	125,718,000	(125,024,000)	973,000
Net loss														(11,039,000)	(11,039,000)
Reclassification of warrant liability to equity													197,000		197,000
Conversion of preferred stock to common stock															0
Issuance of common stock in connection with offering, net of offering costs (in shares)												5,838,000
Issuance of common stock in connection with offering, net of offering costs												$ 58,000	5,162,000		5,220,000
Issuance of common stock in connection with exercise of warrants (in shares)												7,791,000
Issuance of common stock in connection with exercise of warrants												$ 78,000	16,128,000		$ 16,206,000
Issuance of common stock for option exercises (in shares)												20,000			20,000
Issuance of common stock for option exercises												$ 1,000	6,000		$ 7,000
Issuance of RSUs (in shares)					193,000			2,000
Issuance of RSUs					$ 2,000	218,000	220,000		$ 2,000	$ 2,000
Stock-based compensation expense related to employee and director stock options													415,000		415,000
Stock-based compensation expense related to non-employee stock options													64,000		64,000
Stock option modification													53,000		53,000
Balance (in shares) at Dec. 31, 2020											0	41,782,000
Balance at Dec. 31, 2020											$ 0	$ 418,000	147,963,000	(136,063,000)	12,318,000
Net loss														(5,824,000)	(5,824,000)
Issuance of preferred stock and common stock warrants, net of offering costs (in shares)											15
Issuance of preferred stock and common stock warrants, net of offering costs											$ 735				735
Conversion of preferred stock to common stock (in shares)											(1,000)	2,823,000
Conversion of preferred stock to common stock											$ (55,000)				(55,000)
Conversion of preferred stock to common stock												$ 28,000	27,000
Beneficial conversion feature upon issuance of preferred stock													735,000		735,000
Deemed dividend from beneficial conversion feature of preferred stock													735,000		735,000
Issuance of common stock in connection with offering, net of offering costs (in shares)												2,673,000
Issuance of common stock in connection with offering, net of offering costs												$ 27,000	1,749,000		$ 1,776,000
Issuance of common stock for option exercises (in shares)															0
Issuance of RSUs (in shares)					328,000							160
Issuance of RSUs					$ 3,000	$ 217,000	$ 220,000					$ 2	(2)
Stock-based compensation expense related to employee and director stock options													693,000		$ 693,000
Stock-based compensation expense related to non-employee stock options													240,000		240,000
Issuance of warrants													13,000		13,000
Deemed dividend from beneficial conversion feature of preferred stock													(735,000)		(735,000)
Balance (in shares) at Dec. 31, 2021											14,000	47,766,000
Balance at Dec. 31, 2021											$ 680,000	$ 478,000	$ 150,900,000	$ (141,887,000)	$ 10,171,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating activities:
Net loss	$ (5,824)	$ (11,039)	$ (9,658)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	119	51	65
Gain from early operating lease termination	0	(54)	0
Impairment of property and equipment	0	0	32
Loss on disposal of property and equipment	0	1	3
Impairment of operating lease right-of-use assets	0	0	125
Stock option modification expense	0	53	105
Non-cash (gain) loss on changes in fair value of warrant liability	(4,615)	5,216	(749)
Non-cash (gain) on changes in fair value of embedded derivative liability	0	(3)	(424)
Interest expense related to amortization of debt issuance and debt discount	0	141	670
Interest expense related to amortization of debt issuance related to related party note payable	0	2	18
Issuance of warrants for services	0	0	59
Changes in operating assets and liabilities:
Accounts receivable	452	(317)	2,319
Inventory	(243)	(116)	(212)
Prepaid expenses and other current assets	(52)	310	888
Operating lease right-of-use assets	25	816	861
Other assets	0	1	9
Accounts payable and accrued liabilities	(163)	(321)	(1,841)
Operating lease liabilities	(57)	(878)	(1,066)
Deferred rent	0	0	0
Related party note payable	0	73	204
Long-term obligations	0	0	42
Net cash used in operating activities	(9,192)	(4,721)	(7,929)
Investing activities:
Acquisition, net of cash	(11,993)	0	0
Purchases of property and equipment	(52)	(26)	(19)
Net cash used in investing activities	(12,045)	(26)	(19)
Financing activities:
Proceeds from preferred stock issuances, net	14,908	0	2,598
Proceeds from common stock issuances, net	1,776	5,220	6,698
Proceeds from exercise of warrants	0	7,098	67
Proceeds from exercise of options, net	0	7	189
Proceeds from issuance of related party note payable	0	0	1,000
Proceeds from stock options & RSUs sold to cover taxes	0	0	4
Proceeds from convertible notes, net of discount	0	0	2,000
Proceeds from line of credit	105	0	0
Payment on the convertible note (Note 12)	0	(1,563)	(652)
Payment on the related party loan (Note 11)	0	(1,000)	0
Debt issuance cost	0	0	(202)
Net cash provided by financing activities	16,789	9,762	11,702
Net (decrease) increase in cash, cash equivalents, and restricted cash	(4,448)	5,015	3,754
Cash, cash equivalents and restricted cash, beginning of year	12,427	7,412	3,658
Cash, cash equivalents and restricted cash, end of year	7,979	12,427	7,412
Supplemental disclosure of cash flow information:
Interest paid	0	49	148
Income taxes paid	21	14	14
Non-cash payment of related party loan accrued interest by offsetting related party accounts receivables - see Note 11	0	277	0
Addition of operating lease, right-of-use asset	376	0	2,473
Fixed asset purchases, included in accounts payable and accrued liabilities	0	0	10
Fair value of warrants issued in connection with financings	14,172	0	5,269
Conversion of preferred stock to common stock	55	0	584
Reclassification of EmeryStation lease security deposit from long term to short term	0	0	65
Reclassification of EmeryStation sublease security deposit from long term to short term	0	0	198
Employees and Directors [Member] | Share-based Payment Arrangement, Option [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense for options and stock issued	693	415	334
Nonemployees [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Issuance of RSUs	233	220	20
Nonemployees [Member] | Share-based Payment Arrangement, Option [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense for options and stock issued	240	64	37
Employee [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Issuance of RSUs	0	2	10
Former Employee [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Issuance of RSUs	0	0	220
Accounting Standards Update 2017-11 [Member]
Supplemental disclosure of cash flow information:
Cumulative effect of adoption of New ASU	0	0	56
The 2019 Ladenburg Warrants [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash (gain) loss on changes in fair value of warrant liability	200
Supplemental disclosure of cash flow information:
Warrant liability transferred to equity in connection with exercise of warrants	0	9,108	553
The 2019 Preferred Warrant and 2019 Common Warrant Liability [Member]
Supplemental disclosure of cash flow information:
Warrant liability transferred to equity in connection with exercise of warrants	$ 0	$ 197	$ 0

Note 1 - Organization

Note 1 - Organization	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1. ORGANIZATION NovaBay Pharmaceuticals, Inc. develops and sells scientifically-created and clinically-proven eyecare and skincare products. Our leading product, Avenova® Antimicrobial Lid and Lash Solution (“Avenova Spray”), is proven in laboratory testing to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is formulated with our proprietary, stable and pure form of hypochlorous acid and is cleared by the U.S. Food and Drug Administration (“FDA”) for sale in the United States. Avenova Spray is available direct to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease. Other eyecare products offered under the Avenova eyecare brand include Novawipes by Avenova, Avenova Lubricant Eye Drops, Avenova Moist Heating Eye Compress, and the i-Chek. On November 5, 2021, 30 3, The Company was incorporated under the laws of the State of California on January 19, 2000, no July 1, 2002, February 2007, June 2010, Liquidity Based primarily on the funds available at December 31, 2021, March 29, 2023. may may 19

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") and are expressed in U.S. dollars. Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include contract liabilities related to product sales, useful lives for property and equipment and related depreciation calculations, assumptions for valuing options and warrants, the fair value of contingent consideration, intangible assets, and goodwill, stock-based compensation, income taxes and other contingencies These estimates are based on management’s best estimates and judgment. Actual results may Cash, Cash Equivalents, and Restricted Cash The Company considers all highly-liquid instruments with a stated maturity of three December 31, 2021 2020, The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the consolidated balance sheets that sum to the total of the same reported in the consolidated statements of cash flows (in thousands): December 31, December 31, 2021 2020 Cash and cash equivalents $ 7,504 $ 11,952 Restricted cash included in other assets 475 475 Total cash, cash equivalents, and restricted cash in the consolidated statements of cash flows $ 7,979 $ 12,427 The restricted cash amount included in other assets on the consolidated balance sheets represents amounts held as certificates of deposit for long-term financing and lease arrangements as contractually required by our financial institution and landlord. Concentrations of Credit Risk and Major Partners Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains deposits of cash, cash equivalents and restricted cash with a highly-rated, major financial institution in the United States. Deposits in this bank may not During the year ended December 31, 2021, three December 31, 2020, three KN95 During the years ended December 31, 2021, 2020 2019, Year Ended December 31, 2021 2020 2019 Avenova Spray $ 6,844 $ 5,974 $ 6,347 DERMAdoctor 587 — — KN95 Masks — 3,124 — NeutroPhase 368 524 209 Other products 598 294 — Total product revenue, net 8,397 9,916 6,556 Other revenue, net 24 18 43 Total sales, net $ 8,421 $ 9,934 $ 6,599 During the years ended December 31, 2021, 2020 2019, 10% Year Ended December 31, Major distribution 2021 2020 2019 Avenova Direct via Amazon 59 % 50 % 15 % Avenova distributor A * % * % 17 % Avenova distributor B * % * % 16 % Avenova distributor C * % * % 15 % *Not 10% As of December 31, 2021 2020, 10% Year Ended December 31, Major distribution partner 2021 2020 Major U.S. Retailer 33 % * % Avenova Spray Pharmacy Distributor A 13 % 18 % Avenova Spray Pharmacy Distributor C 11 % 14 % Chongqing Pioneer Pharma Holdings Limited * % 16 % Avenova Spray Pharmacy Distributor B * % 14 % Amazon * % 11 % *Not 10% The Company relies on seven not third may may not may 19 Fair Value of Financial Assets and Liabilities The Company’s financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, and contingent consideration. The Company’s cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company follows Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures three may Level 1 Level 2 Level 3 Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Allowance for Doubtful Accounts The Company charges bad debt expense and records an allowance for doubtful accounts when management believes it to be unlikely that specific invoices will be collected. Management identifies amounts due that are in dispute and believes are unlikely to be collected. Management recorded no reserve for accounts receivable at December 31, 2021 December 31, 2020. Inventory Inventory is comprised of ( 1 2 3 first first December 31, 2021 2020, Property and Equipment, net Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five seven three five five seven The costs of normal maintenance, repairs, and minor replacements are expensed as incurred. Business Combinations We account for 805, Business Combinations The determination of estimated fair value requires us to make significant estimates and assumptions. These fair value determinations require judgment and involve the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, discount rates, and asset lives, among other items. As a result, we may one Transaction costs associated with business combinations are expensed as they are incurred. Goodwill and Intangible Assets Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination. Intangible assets are measured at their respective fair values as of the acquisition date and may may one not December 31, 2021 2020, Intangible Asset Fair Value (in thousands) Useful Life (in years) Amortization Method Customer relationships $ 290 7 Straight line Trade secrets / product formulations 2,890 9 Straight line Trade names 2,080 Indefinite N/A Goodwill 4,528 Indefinite N/A $ 9,788 Valuation of Contingent Consideration Resulting from a Business Combination In connection with certain acquisitions, we may Increases or decreases in fair value of the contingent consideration liabilities can result from updates to assumptions such as the expected timing or probability of achieving the specified milestones. Significant judgment is employed in determining these assumptions as of the acquisition date and for each subsequent period. Updates to assumptions could have a significant impact on our results of operations in any given period. Actual results may Impairment of Long-Lived Assets The Company accounts for long-lived assets, other than goodwill and intangible assets, and operating lease right-of-use assets in accordance with ASC 360, Property, Plant and Equipment may may not no not no December 31, 2021 2020, Leases At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not may The Company has elected to combine lease and non-lease components as a single component for all leases in which it is a lessee or a lessor. The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current. Comprehensive Income (Loss) ASC 220, Comprehensive Income, Revenue Recognition Revenue is recognized from sale of goods in accordance with ASC 606, Revenue from Contracts with Customers 606” 606, 606, five 606: i. identify the contract(s) with a customer; ii. identify the performance obligations in the contract; iii. determine the transaction price; iv. allocate the transaction price to the performance obligations in the contract; and v. recognize revenue when (or as) the entity satisfies performance obligations. Revenue is generated through the Company’s webstores, Avenova.com and DERMAdoctor.com, for Avenova Spray and DERMAdoctor direct to consumer sales which are recognized upon fulfillment, which generally occurs upon delivery of the related products to a third Revenue generated through Amazon.com and Walmart.com third The Company also generates Avenova Spray revenue through major pharmacy distribution partners. Product supply of Avenova Spray is the only performance obligation contained in these arrangements, and the Company recognizes product revenue upon transfer of control to its major distribution partners at the amount of consideration that the Company expects to be entitled to, generally upon delivery to the distributor on a “sell-in” basis. Upon recognition of product sales, contract liabilities are recorded for invoiced amounts that are subject to significant reversal, including product revenue allowances for cash consideration paid to customers for services, discounts, rebate programs, and product returns. The Company derives its rate of return from historical data and updates its return rate assumption quarterly. Payment for product supply is typically due 30 days after control transfers to the distributor. Revenue generated through the Company’s partner pharmacies is recognized when control of the product transfers to the end customer. Revenue for product sales to other retailers, such as Costco and CVS, is generally recognized upon transfer of control to the retailer, which generally occurs upon delivery of the related products to a third Cost of Goods Sold Cost of goods sold includes third Research and Development Costs The Company charges research and development costs to expense as incurred. These costs include all costs associated with research, development and regulatory activities, including submissions to the Food and Drug Administration (“FDA”). Patent Costs Patent costs, including legal expenses, are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the consolidated statements of operations and comprehensive loss. Advertising Costs Advertising costs are expensed in the period in which the costs are incurred. Advertising expenses were $3.2 million, $1.7 million, and $0.5 million, respectively, for the years ended December 31, 2021, 2020, 2019. Stock-Based Compensation The Company’s stock-based compensation includes grants of stock options and restricted stock units (“RSUs”) to employees, consultants and non-employee directors. The expense associated with these grants is recognized in the Company’s consolidated statements of stockholders’ equity based on their fair values as they are earned under the applicable vesting terms. For stock options granted, the fair value of the stock options is estimated using a Black-Scholes option pricing model. See Note 15, Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not not Common Stock Warrant Liabilities The Company accounts for common stock purchase warrants issued in connection with its equity offerings in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity 815, Derivatives and Hedging The Company accounts for common stock purchase warrants issued in connection with share-based compensation arrangements in accordance with the provisions of ASC 718, Stock Compensation, 480, Distinguishing Liabilities from Equity The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company), (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement) or (iii) do not 718, Stock Compensation, For warrants that are classified as liabilities, the Company records the fair value of the warrants at each balance sheet date and records changes in the estimated fair value as a non-cash gain or loss in the consolidated statements of operations and comprehensive loss. The fair values of these warrants are determined using the Black-Scholes option pricing model, the Binomial Lattice (“Lattice”) valuation model, or the Monte Carlo simulation model where deemed appropriate. These values are subject to a significant degree of management’s judgment. Net Loss per Share The Company computes net loss per share by presenting both basic and diluted earnings (loss) per share (“EPS”). Basic EPS is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method. In computing diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods because their effect would be anti-dilutive. For the year ended December 31, 2021, December 31, 2021, not The following table sets forth the calculation of basic EPS and diluted EPS (in thousands, except per share amounts): Year Ended December 31, 2021 2020 2019 Numerator Net loss $ (5,824 ) $ (11,039 ) $ (9,658 ) Less: Preferred deemed dividend 735 — 800 Less: Retained earnings reduction related to warrants down round feature triggered — — 29 Net loss attributable to common stockholders, basic and diluted $ (6,559 ) $ (11,039 ) $ (10,487 ) Denominator Weighted average shares outstanding, basic and diluted 43,657 35,076 21,641 Net loss per share, basic and diluted $ (0.15 ) $ (0.31 ) $ (0.48 ) The following outstanding stock options and stock warrants were excluded from the diluted EPS computation as their effect would have been anti-dilutive (in thousands): Year Ended December 31, 2021 2020 2019 Stock options 4,449 3,165 2,183 Stock warrants 7,082 7,067 8,588 11,531 10,232 10,771 Recent Accounting Pronouncements In August 2018, 2018 13, Fair Value Measurement (Topic 820 2018 13” 2018 13 January 1, 2020, not In June 2016, 2016 13, Financial Instruments Credit Losses (Topic 326 2016 13” 2016 13 2016 13 January 1, 2023. January 1, 2023. In December 2019, 2019 12, Income Taxes (Topic 740 Simplifying the Accounting for Income Taxes January 1, 2021, not In August 2020, 2020 06, Debt Debt with Conversion and Other Options (Subtopic 470 20 Contracts in Entity s Own Equity (Subtopic 815 40 s Own Equity 2020 06” . 2020 06 1 2 2020 06 no December 15, 2021, no December 15, 2020. 2020 06 first 2022. January 1, 2022, not

Note 3 - Business Combination

Note 3 - Business Combination	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Business Combination Disclosure [Text Block]	NOTE 3. On November 5, 2021, 100% two January 1, 2020 ( Unaudited Pro Forma Year Ended December 31, 2021 2020 Revenue $ 12,767 $ 18,170 Net Profit (Loss) $ (4,918 ) $ (11,647 ) The pro forma financial information is not January 1, 2020, may December 31, 2020. The Company funded the closing purchase price in part through the 2021 14, The Acquisition is accounted for as a business combination in accordance to ASC 805, Business Combinations The following table sets forth the final allocation of the purchase price for the DERMAdoctor Acquisition to the fair value of the identifiable tangible and intangible assets acquired and liabilities assumed from DERMAdoctor (in thousands): Fair Value Tangible net assets and liabilities: Cash and cash equivalents $ 12 Accounts receivable, net of allowance for doubtful accounts 1,015 Inventory, net of allowance 2,369 Prepaid expenses and other current assets 150 Property and equipment, net 62 Other intangible assets 54 Accounts payable (200 ) Accrued liabilities (683 ) Total net assets 2,779 Intangible Assets: Customer relationships 290 Trade secrets / product formulations 2,890 Trade names 2,080 Total intangible assets 5,260 Net assets acquired 8,039 Purchased consideration 12,561 Goodwill $ 4,528 Goodwill is primarily attributable to assembled workforce, expected synergies and other factors. The fair values of the identifiable intangible assets acquired at the date of the DERMAdoctor Acquisition are as follows (in thousands): Intangible Asset Fair Value Useful Life (in years) Amortization Method Customer relationships $ 290 7 Straight line Trade secrets / product formulations 2,890 9 Straight line Trade names 2,080 Indefinite N/A Goodwill 4,528 Indefinite N/A $ 9,788 The valuations of intangible assets incorporate significant unobservable inputs and require significant judgment and estimates, including the amount and timing of future cash flows. The Company recognized approximately $1.2 million of transaction costs in the year ended December 31, 2021. The Company’s management reviews financial results and manages the business on an aggregate basis in accordance with ASC 280. 1 2 21,

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 4. The Company follows ASC 820, Fair Value Measurements and Disclosures The Company’s cash equivalents are classified within Level 1 1 As of December 31, 2021, 2021 3 13, 14, As of December 31, 2020, no December 31, 2020 2019 2019 2019 2019 2019 July 2020 ( 14, 2019 July 2020 ( 14, The embedded derivative liability related to the Convertible Note (as defined below) was fully settled in September 2020. 12, third 2020. The following table presents the Company's assets measured at fair value on a recurring basis as of December 31, 2021 ( Fair Value Measurements Using Balance at Quoted Prices in Significant Significant December 31, Active Markets Other Unobservable 2021 for Identical Observable Inputs Items Inputs (Level 3) (Level 1) (Level 2) Assets Restricted cash held as a certificate of deposit $ 324 $ 324 $ — $ — Deposit held as a certificate of deposit 151 151 — — Total assets $ 475 $ 475 $ — $ — Liabilities Warrant liability $ 9,558 — — $ 9,558 Contingent earnout liability 561 — — 561 Total liabilities $ 10,119 $ — $ — $ 10,119 The following table presents the Company's assets measured at fair value on a recurring basis as of December 31, 2020 ( Fair Value Measurements Using Balance at Quoted Prices in Significant Significant December 31, Active Markets Other Unobservable 2020 for Identical Observable Inputs Items Inputs (Level 3) (Level 1) (Level 2) Assets Restricted cash held as a certificate of deposit $ 324 $ 324 $ — $ — Deposit held as a certificate of deposit 151 151 — — Total assets $ 475 $ 475 $ — $ — There were no December 31, 2020. The following is a reconciliation of the beginning and ending balances for the liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3 December 31, 2021 ( Fair value of warrant liability at December 31, 2020 $ — Fair value of 2021 Warrants issued 14,172 Decrease in fair value of 2021 Warrants (4,614 ) Fair value of warrant liability at December 31, 2021 $ 9,558 The following is a reconciliation of the beginning and ending balances for the liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3 December 31, 2020 ( Fair value of warrant liability and embedded derivative liability at December 31, 2019 $ 4,092 Increase in fair value of warrant liability 5,238 Decrease in fair value of embedded derivative liability (2 ) Decrease in fair value related to warrants expired (22 ) Fair value of warrant liability transferred to equity upon exercise (9,108 ) Fair value of 2019 Ladenburg Warrant liability transferred to equity upon warrant modification (197 ) Elimination of embedded derivative liability upon settlement of convertible note (1 ) Fair value of warrant liability and embedded derivative liability at December 31, 2020 $ —

Note 5 - Prepaid Expenses and O

Note 5 - Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Prepaid Expenses and Other Current Assets [Text Block]	NOTE 5. Prepaid expenses and other current assets consisted of the following (in thousands): December 31, December 31, 2021 2020 Prepaid inventory $ 368 $ — Prepaid insurance 138 165 Prepaid consulting services 68 — Prepaid sales rebates 19 144 Prepaid security deposit for lease — 65 Prepaid dues and subscription 18 53 Prepaid rent 14 — Prepaid patents 9 47 Other 144 102 Total prepaid expenses and other current assets $ 778 $ 576

Note 6 - Inventory

Note 6 - Inventory	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE 6. Inventory consisted of the following (in thousands): December 31, December 31, 2021 2020 Raw materials and supplies $ 1,179 $ 159 Finished goods 2,682 685 Less: Reserve for excess and obsolete inventory (641 ) (236 ) Total inventory, net $ 3,220 $ 608

Note 7 - Property and Equipment

Note 7 - Property and Equipment	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	NOTE 7. Property and equipment consisted of the following (in thousands): December 31, December 31, 2021 2020 Office and laboratory equipment $ 20 $ 20 Furniture and fixtures 157 157 Computer equipment and software 464 365 Production equipment 114 65 Leasehold improvements 79 79 Total property and equipment, at cost 834 686 Less: accumulated depreciation and amortization (641 ) (602 ) Total property and equipment, net $ 193 $ 84 Depreciation and amortization expense was $59 thousand, $51 thousand, and $65 thousand for the years ended December 31, 2021, 2020 2019, During the years ended December 31, 2021 2020,

Note 8 - Accrued Liabilities

Note 8 - Accrued Liabilities	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 8. Accrued liabilities consisted of the following (in thousands): December 31, December 31, 2021 2020 Contract liabilities (see Note 16) $ 1,289 $ 730 Employee payroll and benefits 443 632 Sublease security deposit — 198 Inventory purchases — 181 Consulting service — 98 Other 360 276 Total accrued liabilities $ 2,092 $ 2,115

Note 9 - Line of Credit

Note 9 - Line of Credit	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	NOTE 12. On March 26, 2019, March 26, 2019. September 26, 2020, third 2020. During the year ended December 31, 2020, December 31, 2020.
Line of Credit [Member]
Notes to Financial Statements
Debt Disclosure [Text Block]	NOTE 9. At the time of the DERMAdoctor Acquisition, DERMAdoctor had a line of credit agreement with Bank Midwest for $500 thousand. There was no balance outstanding on the line of credit at the time of Acquisition Closing. The agreement was terminated and repaid in full subsequent to December 31, 2021 January 6, 2022. December 31, 2021. December 31, 2021,

Note 10 - Commitments and Conti

Note 10 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 10. Indemnification Agreements As permitted under Delaware law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and may not December 31, 2021. In the normal course of business, the Company provides indemnification of varying scope under its agreements with other companies, typically its clinical research organizations, investigators, clinical sites, suppliers, and others. Pursuant to these agreements, it generally indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified parties in connection with the use or testing of its products or product candidates or with any U.S. patent or any copyright or other intellectual property infringement claims by any third not December 31, 2021. Legal Matters As of December 31, 2021, no Leases The Company leases office space for its corporate headquarters located in Emeryville, California. The initial lease term is through February 28, 2022. one five December 31, 2021, January 19, 2022, July 31, 2027 ( 22, We are also party to a lease for 19,136 square feet of space located in Riverside, Missouri, which we utilize for light manufacturing, storage, distribution of products and administrative functions. The lease commenced on October 1, 2019 December 31, 2024. The Company also had a lease commitment for laboratory facilities and office space at EmeryStation North in Emeryville, California (“EmeryStation”) under an operating lease. In July 2016, September 8, 2016. August 31, 2020 July 31, 2020. December 31, 2020. In calculating the present value of the lease payments, the Company has elected to utilize its incremental borrowing rate based on the original lease term and not not not The components of net lease costs for the years ended December 31, 2021 2020 Lease Costs Year Ended December 31, 2021 2020 Operating lease cost $ 418 $ 826 Sublease income — (421 ) Net lease cost $ 418 $ 405 Other information Operational cash flow used for operating leases $ 475 $ 927 The Company has measured its operating lease liabilities at its incremental borrowing rate over the remaining term for each operating lease. The weighted average remaining lease term and the weighted average discount rate are summarized as follows: Year Ended December 31, 2021 2020 Weighted-average remaining lease term (in years) 2.5 1.2 Weighted-average discount rate 6 % 12 % Future lease payments under non-cancelable leases as of December 31, 2021 2022 $ 216 2023 129 2024 130 Thereafter — Total future minimum lease payments 475 Less imputed interest (29 ) Total $ 446 Reported as: Operating lease liability $ 200 Operating lease liability- non-current 246 Total $ 446 Contracts On May 13, 2020, September 4, 2020 February 4, 2021. 2 January 22, 2021. On April 16, 2020, 2 December 31, 2021. December 31, 2020, no In connection with the Microprofit Agreement, on April 16, 2020, June 29, 2020. December 31, 2021.

Note 11 - Related Party Note Pa

Note 11 - Related Party Note Payable	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Related Party Notes Payable [Text Block]	NOTE 11. PAYABLE On February 27, 2019, June 25, 2019 May 14, 2020 ( 65,178 40ml second May 14, 2020, 14, two 2020. December 31, 2020, In connection with the Promissory Note, the Company one March 1, 2020. no The interest expense recognized, including amortization of the issuance costs, was $75 thousand during the year ended December 31, 2020. December 31, 2021.

Note 12 - Convertible Note

Note 12 - Convertible Note	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	NOTE 12. On March 26, 2019, March 26, 2019. September 26, 2020, third 2020. During the year ended December 31, 2020, December 31, 2020.

Note 13 - Warrant Liability

Note 13 - Warrant Liability	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Other Liabilities Disclosure [Text Block]	NOTE 13. July 2011 The Company issued the July 2011 14, third 2011. July 2011 480, Distinguishing Liabilities from Equity July 2011 On March 6, 2020, July 2011 no July 2011 December 31, 2020 December 31, 2021. October 2015 The Company issued the October 2015 14, third 2015. October 2015 480, Distinguishing Liabilities from Equity October 2015 During the fourth 2020, October 2015 On October 27, 2020, October 2015 October 2015 December 31, 2020 December 31, 2021. 2019 As further described in Note 14, 2019 2019 2019 third 2019. 2019 2019 2019 480, Distinguishing Liabilities from Equity Upon issuance in the third 2019, 2019 2019 2019 In the third 2020, 14, 2019 2019 2019 2019 Assumptions 2019 Domestic Warrants 2019 Foreign Warrants Expected price volatility 178 % 178 % Expected term (in years) 4.57 4.57 Risk-free interest rate 0.25 % 0.27 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrant $ 1.18 $ 1.54 There were no 2019 2019 December 31, 2020 December 31, 2021. In the third 2020, 14, 2019 2019 no 2019 Expected price volatility 186 % Expected term (in years) 4.05 Risk-free interest rate 0.22 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 1.17 The 2019 no 2019 December 31, 2021. November 2021 As further described in Note 14, 2021 fourth 2021. 2021 480, Distinguishing Liabilities from Equity 2021 December 31, 2021 2021 2021 December 31, 2021, January 31, 2022. Upon issuance, the fair value of the 2021 November 2, 2021: Expected price volatility 84.9 % Expected term (in years) 6.2 Risk-free interest rate 1.29 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 0.38 As of December 31, 2021, 2021 Expected price volatility 87 % Expected term (in years) 6.0 Risk-free interest rate 1.31 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 0.25

Note 14 - Stockholders' Equity

Note 14 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 14. Preferred Stock The Company is authorized to issue up to 5,000,000 shares of preferred stock with rights and preferences as may On October 29, 2021, “2021 “2021 2021 November 2, 2021. The 2021 not 713 37,500,000 37,500,000 December 17, 2021 ( January 31, 2022, December 31, 2021 six 6 Each share of the Preferred Stock that we issued in the Private Placement had a purchase price of $1,000 per share and is initially convertible at a conversion price of $0.40 into 2,500 shares of Common Stock, or an aggregate of 37,500,000 2021 no December 31, 2021. not The Company allocated the net proceeds between the Preferred Stock and the 2021 first 2021 13, 2021 In connection with the issuance of the Preferred Stock, the Company recorded a beneficial conversion feature of $0.7 million as a discount to Preferred Stock and an increase to additional paid in capital. The Company fully amortized the discount related to the beneficial conversion feature on the deemed dividend in the consolidated statements of operations and comprehensive loss upon approval of the Share Issuance Proposal in the fourth 2021. The Company incurred total issuance costs of $1.7 million in conjunction with the 2021 December 31, 2021. There were 14 thousand shares of the Preferred Stock outstanding as of December 31, 2021. Common Stock April 2020 In the second 2020, 2020 8 April 27, 2020 September 15, 2020. second 2020, 2020 May 2021 In the second 2021, 2021 8 May 14, 2021. second 2021, 2021 Common Stock Warrants July 2011 In the third 2011, “July 2011 July 2011 July 5, 2016. October 2015, July 2011 March 6, 2020. February 2016 May 2019, July 2011 In March 2020, July 2011 December 31, 2021, July 2011 March 2015 In the first 2015, “March 2015 March 2015 March 2015 March 6, 2020 March 2015 September 6, 2015. October 2015, March 2015 September 6, 2015 March 6, 2020. February 2016 May 2019, July 2011 During the first 2020, March 2015 first 2020, March 2015 December 31, 2021, March 2015 October 2015 In the fourth 2015, “October 2015 October 27, 2020. February 2016 May 2019, October 2015 fourth 2020, October 2015 During the fourth 2020, October 2015 December 31, 2021, October 2015 June 2019 June 2019 During the second 2019, “June 2019 six The June 2019 June 17, 2020. June 2019 During the first 2020, June 2019 six During the second 2020, June 2019 six second 2020, June 2019 December 31, 2021, June 2019 2019 2019 2019 2019 July 2020 In the third 2019, “2019 “2019 2019 February 13, 2025. The Company allocated the proceeds between the common stock and 2019 first 2019 13, 2019 Ladenburg served as the placement agent for the transaction in exchange for a commission representing six August 8, 2024 ( “2019 The Company incurred total issuance costs of $0.5 million in conjunction with the 2019 2019 12, 2019 During the third 2020, 2019 2019 six 2019 During the third 2020, 2019 2019 2019 2019 1 2019 2019 2 “July 2020 100% 2019 2019 The July 2020 nine July 2020 five 2019 2019 July 2020 one not July 2020 During the third 2020, 2019 13 2019 no TLF Bio Innovation 2021 On January 15, 2021, five The details of all outstanding warrants as of December 31, 2021 Warrants (in thousands) Weighted- Average Exercise Price Outstanding at December 31, 2020 7,067 $ 1.63 Warrants granted 15 $ 0.67 Warrants expired — $ — Outstanding at December 31, 2021 7,082 $ 1.63

Note 15 - Equity-based Compensa

Note 15 - Equity-based Compensation	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	NOTE 15. Equity Compensation Plans In October 2007, 2007 “2007 2007 March 15, 2017. 2007 2007 no ten 2007 December 31, 2020. In March 2017, 2017 “2017 June 2, 2017, 2017 not 2007 2017 first January 1, 2018 January 1, 2027 4 2017 January 15, 2021, 2017 December 31, 2021, 1,842,993 2017 Under the terms of the 2017 may not not not ten not five 10% four 2007 2017 Stock Option Summary The following table summarizes information about the Company’s stock options and restricted stock outstanding at December 31, 2021, 2020, December 31, 2021: (in thousands, except years and per share data) Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2020 3,165 $ 2.05 7.6 $ 189 Options granted 516 $ 0.66 Restricted stock units granted 1,528 $ — Restricted stock units vested (488 ) $ — Options forfeited/cancelled (272 ) $ 2.35 Outstanding at December 31, 2021 4,449 $ 1.39 7.6 $ 460 Vested and expected to vest at December 31, 2021 4,125 $ 1.46 7.5 $ 406 Vested at December 31, 2021 2,150 $ 2.42 5.4 $ 8 Exercisable at December 31, 2021 2,150 $ 2.42 5.9 $ 8 The aggregate intrinsic value in the table above is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of the Company’s common stock as quoted on the NYSE American as of December 31, 2021 December 31, 2021. December 31, 2020 December 31, 2020. December 31, 2019 December 31, 2019. As of December 31, 2021, Stock Option Awards to Employees and Directors The Company grants options to purchase common stock to its employees and directors at prices equal to or greater than the market value of the stock on the dates the options are granted. The Company has estimated the value of stock option awards as of the date of grant by applying the Black-Scholes option pricing model using the single-option valuation approach. The application of this valuation model involves assumptions that are judgmental and subjective in nature. See Note 2, During the years ended December 31, 2021, 2020, 2019, The weighted-average assumptions used in determining the value of options are as follows: Year Ended December 31, Assumptions 2021 2020 2019 Expected price volatility 164 % 161 % 112 % Expected term (in years) 6.19 6.45 6.14 Risk-free interest rate 1.05 % 0.45 % 1.99 % Dividend yield 0.00 % 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 0.64 $ 0.94 $ 0.31 Expected Price Volatility Expected Term Risk-Free Interest Rate Dividend Yield not Forfeitures are estimated at the time of grant and reduce compensation expense ratably over the vesting period. This estimate is adjusted periodically based on the extent to which actual forfeitures differ, or are expected to differ, from the previous estimate. During the year ended December 31, 2021, December 31, 2020, one December 31, 2019. For the years ended December 31, 2021, 2020, 2019, The Company modified stock options held by Mr. Yonghao (Carl) Ma in April 2019, May 2019, July 2019, September 2019, April 2020 August 2020, three three Stock-Based Awards to Non-Employees During the year December 31, 2021, not December 31, 2020, 400,000 19, December 31, 2019, not Stock options granted to non-employees recorded at their fair value on the measurement date and recognized over the respective service or vesting period. The fair value of the stock options granted was calculated using the Black-Scholes-Merton option pricing model based upon the following assumptions: Year Ended December 31, Assumptions 2021 2020 Expected price volatility — 162 % Expected term (in years) — 6.34 Risk-free interest rate — 0.50 % Dividend yield — 0.00 % Weighted-average fair value of options granted during the period $ — $ 0.73 The Company did not December 31, 2021. In connection with Mr. Sieczkarek’s resignation, the Company granted 168 December 31, 2019. two two July 2020, first July 2021, second During the fourth December 31, 2019, two For the years ended December 31, 2021, 2020, 2019, Summary of Stock-Based Compensation Expense A summary of the stock-based compensation expense included in results of operations for the options and restricted stock awards discussed above is as follows (in thousands): Year Ended December 31, 2021 2020 2019 Research and development $ 10 $ 23 $ 42 Sales and marketing 129 85 93 General and administrative 794 424 351 Total stock-based compensation expense $ 933 $ 532 $ 486

Note 16 - License, Collaboratio

Note 16 - License, Collaboration and Distribution Agreements	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
License, Collaboration, and Distribution Agreements [Text Block]	NOTE 16. Transactions under the Company’s major distribution agreements are recognized upon transfer of control of product sold to its major distribution partners at the amount of consideration that the Company expects to be entitled to. The Company records contract liabilities for the amounts that are estimated to be subject to significant reversal, including allowances for services, discounts, rebate programs, and product returns. The following table presents changes in the Company's contract assets and liabilities for the year ended December 31, 2021 ( Balance at Beginning of the Period Additions Deductions Balance at the end of the Period Contract liabilities: deferred revenue $ 2 $ 176 $ (124 ) $ 54 Contract liabilities: accrued liabilities (includes contract assets) 573 1,851 (1,154 ) 1,270 Total $ 575 $ 2,027 $ (1,278 ) $ 1,324 The following table presents changes in the Company's contract assets and liabilities for the year ended December 31, 2020 ( Balance at Beginning of the Period Additions Deductions Balance at the end of the Period Contract liabilities: deferred revenue $ — $ 2 $ — $ 2 Contract liabilities: accrued liabilities (includes contract assets) 434 2,338 (2,199 ) 573 Total $ 434 $ 2,340 $ (2,199 ) $ 575 For the years ended December 31, 2021, 2020 2019, Year Ended December 31, 2021 2020 2019 Revenue recognized in the period from: Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied $ 573 $ 434 $ 1,473 New activities in the period: Performance obligations satisfied 7,848 9,500 5,126 $ 8,421 $ 9,934 $ 6,599 Avenova Spray Pharmacy Distribution Agreements and Specialty Pharmacies Avenova Spray is made available in local pharmacies and major pharmacy retail chains under nationwide distribution agreements with McKesson Corporation, Cardinal Health and AmerisourceBergen. We have also entered into direct agreements with preferred pharmacy networks as part of our Partner Pharmacy Program. During the years ended December 31, 2021, 2020 2019, Under these product distribution arrangements, the Company had a contract liability balance of $0.9 million as of December 31, 2021 December 31, 2020. December 31, 2021 December 31, 2020, 5, Over-the-Counter Sales of Avenova Spray Avenova Spray was launched online on June 1, 2019 February 2021. December 31, 2021, 2020, 2019

Note 17 - Employee Benefit Plan

Note 17 - Employee Benefit Plan	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Retirement Benefits [Text Block]	NOTE 17. The Company has a 401 not December 31, 2021 2020. 401 January 1, 2022, first

Note 18 - Income Taxes

Note 18 - Income Taxes	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 18. For the years ended December 31, 2021, 2020 2019, Year Ended December 31, 2021 2020 2019 United States $ (5,824 ) $ (11,034 ) $ (9,652 ) International — — — $ (5,824 ) $ (11,034 ) $ (9,652 ) For the years ended December 31, 2021, 2020 2019, Year Ended December 31, 2021 2020 2019 Current Federal $ — $ — $ — State — 5 6 Other — — — Total current tax expense — 5 6 Deferred Federal — — — State — — — Other — — — Total deferred tax expense — — — Income tax provision $ — $ 5 $ 6 Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards. The tax effects of significant items comprising the Company's deferred taxes as of December 31, 2021 2020 Year Ended December 31, 2021 2020 Deferred tax assets: Net operating losses $ 33,455 $ 31,115 Stock options 884 790 Research and development credits 641 641 Accruals 306 267 Operating lease liabilities 19 109 Property and equipment 10 2 Other deferred tax assets 376 81 Total deferred tax assets 35,691 33,005 Deferred tax liabilities: Operating lease right-of-use assets (19 ) (108 ) Total deferred tax liabilities (19 ) (108 ) Valuation allowance (35,672 ) (32,897 ) Net deferred taxes $ — $ — ASC 740 not." not On March 27, 2020, none The valuation allowance increased by $2.8 million, $1.3 million and $2.2 million during the years ended December 31, 2021, 2020 2019, Net operating loss and tax credit carryforwards as of December 31, 2021, Expiration Amount Years Net operating losses, federal (Post December 31, 2017) $ 30,989 Does Not Expire Net operating losses, federal (Pre January 1, 2018) $ 94,886 Beginning in 2024 Net operating losses, state $ 106,784 Beginning in 2028 Tax credits, federal $ 1,321 Beginning in 2026 Tax credits, state $ 325 Indefinite A reconciliation of the beginning and ending balance of unrecognized income tax benefits follows (in thousands): Year Ended December 31, 2021 2020 Unrecognized benefit - beginning of period $ 974 $ 974 Change during the period — — Unrecognized benefit - end of period $ 974 $ 974 The entire amount of the unrecognized tax benefits would not not 12 not 2004 2021 2006 2021 not The effective tax rate of the Company's provision (benefit) for income taxes differs from the federal statutory rate as follows: Year Ended December 31, 2021 2020 2019 Statutory rate 21.0 % 21.0 % 21.0 % State tax 11.2 % 3.2 % 3.1 % Change in valuation allowance (47.7 %) (11.7 %) (23.0 %) Warrant/equity expenses 16.7 % (10.3 %) 1.7 % Stock-based compensation expense (1.1 %) (4.0 %) (3.7 %) Other (0.1 %) 1.7 % (0.3 %) Impact of 162m — % — % 1.1 % Total 0.0 % (0.1 %) (0.1 %)

Note 19 - Related Party Transac

Note 19 - Related Party Transactions	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 19. Related Party Revenue The following table summarizes information about the Company’s related party revenue and cost of goods sold during the years ended December 31, 2021, 2020 2019, Year Ended December 31, 2021 2020 2019 Related party revenue: NeutroPhase $ 368 $ 524 $ 209 Licensing — — 41 Total related party revenue $ 368 $ 524 $ 250 Cost of goods sold NeutroPhase $ 325 $ 384 $ 176 Licensing — — — Total related party expenses $ 325 $ 384 $ 176 Related party accounts receivable was $0.1 million and $0.2 million as of December 31, 2021 December 31, 2020, Other Related Party Expenses During the year ended December 31, 2021, KN95 December 31, 2021, December 31, 2020. The following table summarizes information about the Company’s other related party expenses excluding stock-based compensation during the years ended December 31, 2021, 2020 2019, Year Ended December 31, 2021 2020 2019 Commissions to China Kington related to: OP Private Placement $ — $ — $ — June 2019 Private Placement — — 144 August 2019 Private Placement — — 162 Exercise of June 2019 Warrants — 41 — Exercise of 2019 Foreign Warrants — 160 — Promissory Note to Pioneer Pharma (Hong Kong) Company Ltd. — — 20 Total commissions to China Kington — 201 326 Board Director Bob Wu consulting fee — 50 83 Total related party expenses $ — $ 251 $ 409 On November 17, 2020, twelve 2017 one December 31, 2021 2020,

Note 20 - Paycheck Protection P

Note 20 - Paycheck Protection Program	12 Months Ended
	Dec. 31, 2021
COVID 19 Member [Member]
Notes to Financial Statements
Unusual or Infrequent Items, or Both, Disclosure [Text Block]	NOTE 20. On May 6, 2020, March 27, 2020. 2020, September 5, 2020. 1.00% two 2021. no 24 Since the Company determined that there was reasonable assurance that it would meet the conditions for forgiveness of the full loan amount, the Company accounted for the forgivable PPP Loan as a government income grant that we earned through the Company’s compliance with the loan forgiveness criteria. A deferred income liability was recognized upon receipt of the forgivable loan proceeds. The deferred income liability was recognized as other income as Qualifying Expenses were incurred. For the year ended December 31, 2020, No December 31, 2021. The Company received notice, dated May 24, 2021,

Note 21 - Segment Reporting

Note 21 - Segment Reporting	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	NOTE 21. The Company’s chief operating decision maker (“CODM”), who is the Company’s Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance. Prior to the DERMAdoctor Acquisition in November 2021 ( 3, 1 2 Select financial information for each segment is as follows: Year Ended Percentage December 31, 2021 of Total Revenue Optical & Wound Care $ 7,834 93 % Skincare 587 7 % Total revenue $ 8,421 100 % Year Ended Percentage December 31, 2021 of Total Gross Margin Optical &Wound Care $ 5,336 95 % Skincare 309 5 % Total gross margin $ 5,645 100 %

Note 22 - Subsequent Events

Note 22 - Subsequent Events	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 22. On January 19, 2022, July 31, 2027. On January 31, 2022, January 31, 2022. In February 2022, not not not

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") and are expressed in U.S. dollars.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include contract liabilities related to product sales, useful lives for property and equipment and related depreciation calculations, assumptions for valuing options and warrants, the fair value of contingent consideration, intangible assets, and goodwill, stock-based compensation, income taxes and other contingencies These estimates are based on management’s best estimates and judgment. Actual results may
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash, Cash Equivalents, and Restricted Cash The Company considers all highly-liquid instruments with a stated maturity of three December 31, 2021 2020, The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the consolidated balance sheets that sum to the total of the same reported in the consolidated statements of cash flows (in thousands): December 31, December 31, 2021 2020 Cash and cash equivalents $ 7,504 $ 11,952 Restricted cash included in other assets 475 475 Total cash, cash equivalents, and restricted cash in the consolidated statements of cash flows $ 7,979 $ 12,427 The restricted cash amount included in other assets on the consolidated balance sheets represents amounts held as certificates of deposit for long-term financing and lease arrangements as contractually required by our financial institution and landlord.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk and Major Partners Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains deposits of cash, cash equivalents and restricted cash with a highly-rated, major financial institution in the United States. Deposits in this bank may not During the year ended December 31, 2021, three December 31, 2020, three KN95 During the years ended December 31, 2021, 2020 2019, Year Ended December 31, 2021 2020 2019 Avenova Spray $ 6,844 $ 5,974 $ 6,347 DERMAdoctor 587 — — KN95 Masks — 3,124 — NeutroPhase 368 524 209 Other products 598 294 — Total product revenue, net 8,397 9,916 6,556 Other revenue, net 24 18 43 Total sales, net $ 8,421 $ 9,934 $ 6,599 During the years ended December 31, 2021, 2020 2019, 10% Year Ended December 31, Major distribution 2021 2020 2019 Avenova Direct via Amazon 59 % 50 % 15 % Avenova distributor A * % * % 17 % Avenova distributor B * % * % 16 % Avenova distributor C * % * % 15 % *Not 10% As of December 31, 2021 2020, 10% Year Ended December 31, Major distribution partner 2021 2020 Major U.S. Retailer 33 % * % Avenova Spray Pharmacy Distributor A 13 % 18 % Avenova Spray Pharmacy Distributor C 11 % 14 % Chongqing Pioneer Pharma Holdings Limited * % 16 % Avenova Spray Pharmacy Distributor B * % 14 % Amazon * % 11 % *Not 10% The Company relies on seven not third may may not may 19
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Assets and Liabilities The Company’s financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, and contingent consideration. The Company’s cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company follows Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures three may Level 1 Level 2 Level 3 Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Doubtful Accounts The Company charges bad debt expense and records an allowance for doubtful accounts when management believes it to be unlikely that specific invoices will be collected. Management identifies amounts due that are in dispute and believes are unlikely to be collected. Management recorded no reserve for accounts receivable at December 31, 2021 December 31, 2020.
Inventory, Policy [Policy Text Block]	Inventory Inventory is comprised of ( 1 2 3 first first December 31, 2021 2020,
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment, net Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five seven three five five seven The costs of normal maintenance, repairs, and minor replacements are expensed as incurred.
Business Combinations Policy [Policy Text Block]	Business Combinations We account for 805, Business Combinations The determination of estimated fair value requires us to make significant estimates and assumptions. These fair value determinations require judgment and involve the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, discount rates, and asset lives, among other items. As a result, we may one Transaction costs associated with business combinations are expensed as they are incurred.
Goodwill and Intangible Assets, Policy [Policy Text Block]	Goodwill and Intangible Assets Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination. Intangible assets are measured at their respective fair values as of the acquisition date and may may one not December 31, 2021 2020, Intangible Asset Fair Value (in thousands) Useful Life (in years) Amortization Method Customer relationships $ 290 7 Straight line Trade secrets / product formulations 2,890 9 Straight line Trade names 2,080 Indefinite N/A Goodwill 4,528 Indefinite N/A $ 9,788
Valuation of Contingent Consideration from Business Combination Policy [Policy Text Block]	Valuation of Contingent Consideration Resulting from a Business Combination In connection with certain acquisitions, we may Increases or decreases in fair value of the contingent consideration liabilities can result from updates to assumptions such as the expected timing or probability of achieving the specified milestones. Significant judgment is employed in determining these assumptions as of the acquisition date and for each subsequent period. Updates to assumptions could have a significant impact on our results of operations in any given period. Actual results may
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets The Company accounts for long-lived assets, other than goodwill and intangible assets, and operating lease right-of-use assets in accordance with ASC 360, Property, Plant and Equipment may may not no not no December 31, 2021 2020,
Lessee, Leases [Policy Text Block]	Leases At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not may The Company has elected to combine lease and non-lease components as a single component for all leases in which it is a lessee or a lessor. The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income (Loss) ASC 220, Comprehensive Income,
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition Revenue is recognized from sale of goods in accordance with ASC 606, Revenue from Contracts with Customers 606” 606, 606, five 606: i. identify the contract(s) with a customer; ii. identify the performance obligations in the contract; iii. determine the transaction price; iv. allocate the transaction price to the performance obligations in the contract; and v. recognize revenue when (or as) the entity satisfies performance obligations. Revenue is generated through the Company’s webstores, Avenova.com and DERMAdoctor.com, for Avenova Spray and DERMAdoctor direct to consumer sales which are recognized upon fulfillment, which generally occurs upon delivery of the related products to a third Revenue generated through Amazon.com and Walmart.com third The Company also generates Avenova Spray revenue through major pharmacy distribution partners. Product supply of Avenova Spray is the only performance obligation contained in these arrangements, and the Company recognizes product revenue upon transfer of control to its major distribution partners at the amount of consideration that the Company expects to be entitled to, generally upon delivery to the distributor on a “sell-in” basis. Upon recognition of product sales, contract liabilities are recorded for invoiced amounts that are subject to significant reversal, including product revenue allowances for cash consideration paid to customers for services, discounts, rebate programs, and product returns. The Company derives its rate of return from historical data and updates its return rate assumption quarterly. Payment for product supply is typically due 30 days after control transfers to the distributor. Revenue generated through the Company’s partner pharmacies is recognized when control of the product transfers to the end customer. Revenue for product sales to other retailers, such as Costco and CVS, is generally recognized upon transfer of control to the retailer, which generally occurs upon delivery of the related products to a third
Cost of Goods Sold, Policy [Policy Text Block]	Cost of Goods Sold Cost of goods sold includes third
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs The Company charges research and development costs to expense as incurred. These costs include all costs associated with research, development and regulatory activities, including submissions to the Food and Drug Administration (“FDA”).
Patent Costs Policy [Policy Text Block]	Patent Costs Patent costs, including legal expenses, are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the consolidated statements of operations and comprehensive loss.
Advertising Cost [Policy Text Block]	Advertising Costs Advertising costs are expensed in the period in which the costs are incurred. Advertising expenses were $3.2 million, $1.7 million, and $0.5 million, respectively, for the years ended December 31, 2021, 2020, 2019.
Share-based Payment Arrangement [Policy Text Block]	Stock-Based Compensation The Company’s stock-based compensation includes grants of stock options and restricted stock units (“RSUs”) to employees, consultants and non-employee directors. The expense associated with these grants is recognized in the Company’s consolidated statements of stockholders’ equity based on their fair values as they are earned under the applicable vesting terms. For stock options granted, the fair value of the stock options is estimated using a Black-Scholes option pricing model. See Note 15,
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not not
Warrant Liabilities [Policy Text Block]	Common Stock Warrant Liabilities The Company accounts for common stock purchase warrants issued in connection with its equity offerings in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity 815, Derivatives and Hedging The Company accounts for common stock purchase warrants issued in connection with share-based compensation arrangements in accordance with the provisions of ASC 718, Stock Compensation, 480, Distinguishing Liabilities from Equity The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company), (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement) or (iii) do not 718, Stock Compensation, For warrants that are classified as liabilities, the Company records the fair value of the warrants at each balance sheet date and records changes in the estimated fair value as a non-cash gain or loss in the consolidated statements of operations and comprehensive loss. The fair values of these warrants are determined using the Black-Scholes option pricing model, the Binomial Lattice (“Lattice”) valuation model, or the Monte Carlo simulation model where deemed appropriate. These values are subject to a significant degree of management’s judgment.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company computes net loss per share by presenting both basic and diluted earnings (loss) per share (“EPS”). Basic EPS is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method. In computing diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods because their effect would be anti-dilutive. For the year ended December 31, 2021, December 31, 2021, not The following table sets forth the calculation of basic EPS and diluted EPS (in thousands, except per share amounts): Year Ended December 31, 2021 2020 2019 Numerator Net loss $ (5,824 ) $ (11,039 ) $ (9,658 ) Less: Preferred deemed dividend 735 — 800 Less: Retained earnings reduction related to warrants down round feature triggered — — 29 Net loss attributable to common stockholders, basic and diluted $ (6,559 ) $ (11,039 ) $ (10,487 ) Denominator Weighted average shares outstanding, basic and diluted 43,657 35,076 21,641 Net loss per share, basic and diluted $ (0.15 ) $ (0.31 ) $ (0.48 ) The following outstanding stock options and stock warrants were excluded from the diluted EPS computation as their effect would have been anti-dilutive (in thousands): Year Ended December 31, 2021 2020 2019 Stock options 4,449 3,165 2,183 Stock warrants 7,082 7,067 8,588 11,531 10,232 10,771
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In August 2018, 2018 13, Fair Value Measurement (Topic 820 2018 13” 2018 13 January 1, 2020, not In June 2016, 2016 13, Financial Instruments Credit Losses (Topic 326 2016 13” 2016 13 2016 13 January 1, 2023. January 1, 2023. In December 2019, 2019 12, Income Taxes (Topic 740 Simplifying the Accounting for Income Taxes January 1, 2021, not In August 2020, 2020 06, Debt Debt with Conversion and Other Options (Subtopic 470 20 Contracts in Entity s Own Equity (Subtopic 815 40 s Own Equity 2020 06” . 2020 06 1 2 2020 06 no December 15, 2021, no December 15, 2020. 2020 06 first 2022. January 1, 2022, not

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block]	December 31, December 31, 2021 2020 Cash and cash equivalents $ 7,504 $ 11,952 Restricted cash included in other assets 475 475 Total cash, cash equivalents, and restricted cash in the consolidated statements of cash flows $ 7,979 $ 12,427
Schedules of Concentration of Risk, by Product [Table Text Block]	Year Ended December 31, 2021 2020 2019 Avenova Spray $ 6,844 $ 5,974 $ 6,347 DERMAdoctor 587 — — KN95 Masks — 3,124 — NeutroPhase 368 524 209 Other products 598 294 — Total product revenue, net 8,397 9,916 6,556 Other revenue, net 24 18 43 Total sales, net $ 8,421 $ 9,934 $ 6,599
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Year Ended December 31, Major distribution 2021 2020 2019 Avenova Direct via Amazon 59 % 50 % 15 % Avenova distributor A * % * % 17 % Avenova distributor B * % * % 16 % Avenova distributor C * % * % 15 % Year Ended December 31, Major distribution partner 2021 2020 Major U.S. Retailer 33 % * % Avenova Spray Pharmacy Distributor A 13 % 18 % Avenova Spray Pharmacy Distributor C 11 % 14 % Chongqing Pioneer Pharma Holdings Limited * % 16 % Avenova Spray Pharmacy Distributor B * % 14 % Amazon * % 11 %
Schedule of Intangible Assets and Goodwill [Table Text Block]	Intangible Asset Fair Value (in thousands) Useful Life (in years) Amortization Method Customer relationships $ 290 7 Straight line Trade secrets / product formulations 2,890 9 Straight line Trade names 2,080 Indefinite N/A Goodwill 4,528 Indefinite N/A $ 9,788
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended December 31, 2021 2020 2019 Numerator Net loss $ (5,824 ) $ (11,039 ) $ (9,658 ) Less: Preferred deemed dividend 735 — 800 Less: Retained earnings reduction related to warrants down round feature triggered — — 29 Net loss attributable to common stockholders, basic and diluted $ (6,559 ) $ (11,039 ) $ (10,487 ) Denominator Weighted average shares outstanding, basic and diluted 43,657 35,076 21,641 Net loss per share, basic and diluted $ (0.15 ) $ (0.31 ) $ (0.48 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Year Ended December 31, 2021 2020 2019 Stock options 4,449 3,165 2,183 Stock warrants 7,082 7,067 8,588 11,531 10,232 10,771

Note 3 - Business Combination (

Note 3 - Business Combination (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Business Acquisition, Pro Forma Information [Table Text Block]	Unaudited Pro Forma Year Ended December 31, 2021 2020 Revenue $ 12,767 $ 18,170 Net Profit (Loss) $ (4,918 ) $ (11,647 )
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Fair Value Tangible net assets and liabilities: Cash and cash equivalents $ 12 Accounts receivable, net of allowance for doubtful accounts 1,015 Inventory, net of allowance 2,369 Prepaid expenses and other current assets 150 Property and equipment, net 62 Other intangible assets 54 Accounts payable (200 ) Accrued liabilities (683 ) Total net assets 2,779 Intangible Assets: Customer relationships 290 Trade secrets / product formulations 2,890 Trade names 2,080 Total intangible assets 5,260 Net assets acquired 8,039 Purchased consideration 12,561 Goodwill $ 4,528
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]	Intangible Asset Fair Value Useful Life (in years) Amortization Method Customer relationships $ 290 7 Straight line Trade secrets / product formulations 2,890 9 Straight line Trade names 2,080 Indefinite N/A Goodwill 4,528 Indefinite N/A $ 9,788

Note 4 - Fair Value Measureme_2

Note 4 - Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Fair Value Measurements Using Balance at Quoted Prices in Significant Significant December 31, Active Markets Other Unobservable 2021 for Identical Observable Inputs Items Inputs (Level 3) (Level 1) (Level 2) Assets Restricted cash held as a certificate of deposit $ 324 $ 324 $ — $ — Deposit held as a certificate of deposit 151 151 — — Total assets $ 475 $ 475 $ — $ — Liabilities Warrant liability $ 9,558 — — $ 9,558 Contingent earnout liability 561 — — 561 Total liabilities $ 10,119 $ — $ — $ 10,119 Fair Value Measurements Using Balance at Quoted Prices in Significant Significant December 31, Active Markets Other Unobservable 2020 for Identical Observable Inputs Items Inputs (Level 3) (Level 1) (Level 2) Assets Restricted cash held as a certificate of deposit $ 324 $ 324 $ — $ — Deposit held as a certificate of deposit 151 151 — — Total assets $ 475 $ 475 $ — $ —
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Fair value of warrant liability at December 31, 2020 $ — Fair value of 2021 Warrants issued 14,172 Decrease in fair value of 2021 Warrants (4,614 ) Fair value of warrant liability at December 31, 2021 $ 9,558 Fair value of warrant liability and embedded derivative liability at December 31, 2019 $ 4,092 Increase in fair value of warrant liability 5,238 Decrease in fair value of embedded derivative liability (2 ) Decrease in fair value related to warrants expired (22 ) Fair value of warrant liability transferred to equity upon exercise (9,108 ) Fair value of 2019 Ladenburg Warrant liability transferred to equity upon warrant modification (197 ) Elimination of embedded derivative liability upon settlement of convertible note (1 ) Fair value of warrant liability and embedded derivative liability at December 31, 2020 $ —

Note 5 - Prepaid Expenses and_2

Note 5 - Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	December 31, December 31, 2021 2020 Prepaid inventory $ 368 $ — Prepaid insurance 138 165 Prepaid consulting services 68 — Prepaid sales rebates 19 144 Prepaid security deposit for lease — 65 Prepaid dues and subscription 18 53 Prepaid rent 14 — Prepaid patents 9 47 Other 144 102 Total prepaid expenses and other current assets $ 778 $ 576

Note 6 - Inventory (Tables)

Note 6 - Inventory (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Inventory, Current [Table Text Block]	December 31, December 31, 2021 2020 Raw materials and supplies $ 1,179 $ 159 Finished goods 2,682 685 Less: Reserve for excess and obsolete inventory (641 ) (236 ) Total inventory, net $ 3,220 $ 608

Note 7 - Property and Equipme_2

Note 7 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, December 31, 2021 2020 Office and laboratory equipment $ 20 $ 20 Furniture and fixtures 157 157 Computer equipment and software 464 365 Production equipment 114 65 Leasehold improvements 79 79 Total property and equipment, at cost 834 686 Less: accumulated depreciation and amortization (641 ) (602 ) Total property and equipment, net $ 193 $ 84

Note 8 - Accrued Liabilities (T

Note 8 - Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	December 31, December 31, 2021 2020 Contract liabilities (see Note 16) $ 1,289 $ 730 Employee payroll and benefits 443 632 Sublease security deposit — 198 Inventory purchases — 181 Consulting service — 98 Other 360 276 Total accrued liabilities $ 2,092 $ 2,115

Note 10 - Commitments and Con_2

Note 10 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Lease, Cost [Table Text Block]	Lease Costs Year Ended December 31, 2021 2020 Operating lease cost $ 418 $ 826 Sublease income — (421 ) Net lease cost $ 418 $ 405 Other information Operational cash flow used for operating leases $ 475 $ 927 Year Ended December 31, 2021 2020 Weighted-average remaining lease term (in years) 2.5 1.2 Weighted-average discount rate 6 % 12 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2022 $ 216 2023 129 2024 130 Thereafter — Total future minimum lease payments 475 Less imputed interest (29 ) Total $ 446 Reported as: Operating lease liability $ 200 Operating lease liability- non-current 246 Total $ 446

Note 13 - Warrant Liability (Ta

Note 13 - Warrant Liability (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Derivative Instruments [Table Text Block]	Assumptions 2019 Domestic Warrants 2019 Foreign Warrants Expected price volatility 178 % 178 % Expected term (in years) 4.57 4.57 Risk-free interest rate 0.25 % 0.27 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrant $ 1.18 $ 1.54 Expected price volatility 186 % Expected term (in years) 4.05 Risk-free interest rate 0.22 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 1.17 Expected price volatility 84.9 % Expected term (in years) 6.2 Risk-free interest rate 1.29 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 0.38 Expected price volatility 87 % Expected term (in years) 6.0 Risk-free interest rate 1.31 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 0.25

Note 14 - Stockholders' Equity

Note 14 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrants (in thousands) Weighted- Average Exercise Price Outstanding at December 31, 2020 7,067 $ 1.63 Warrants granted 15 $ 0.67 Warrants expired — $ — Outstanding at December 31, 2021 7,082 $ 1.63

Note 15 - Equity-based Compen_2

Note 15 - Equity-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	(in thousands, except years and per share data) Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2020 3,165 $ 2.05 7.6 $ 189 Options granted 516 $ 0.66 Restricted stock units granted 1,528 $ — Restricted stock units vested (488 ) $ — Options forfeited/cancelled (272 ) $ 2.35 Outstanding at December 31, 2021 4,449 $ 1.39 7.6 $ 460 Vested and expected to vest at December 31, 2021 4,125 $ 1.46 7.5 $ 406 Vested at December 31, 2021 2,150 $ 2.42 5.4 $ 8 Exercisable at December 31, 2021 2,150 $ 2.42 5.9 $ 8
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Year Ended December 31, 2021 2020 2019 Research and development $ 10 $ 23 $ 42 Sales and marketing 129 85 93 General and administrative 794 424 351 Total stock-based compensation expense $ 933 $ 532 $ 486
Nonemployees [Member]
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended December 31, Assumptions 2021 2020 Expected price volatility — 162 % Expected term (in years) — 6.34 Risk-free interest rate — 0.50 % Dividend yield — 0.00 % Weighted-average fair value of options granted during the period $ — $ 0.73
Employees and Directors [Member]
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended December 31, Assumptions 2021 2020 2019 Expected price volatility 164 % 161 % 112 % Expected term (in years) 6.19 6.45 6.14 Risk-free interest rate 1.05 % 0.45 % 1.99 % Dividend yield 0.00 % 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 0.64 $ 0.94 $ 0.31

Note 16 - License, Collaborat_2

Note 16 - License, Collaboration and Distribution Agreements (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Balance at Beginning of the Period Additions Deductions Balance at the end of the Period Contract liabilities: deferred revenue $ 2 $ 176 $ (124 ) $ 54 Contract liabilities: accrued liabilities (includes contract assets) 573 1,851 (1,154 ) 1,270 Total $ 575 $ 2,027 $ (1,278 ) $ 1,324 Balance at Beginning of the Period Additions Deductions Balance at the end of the Period Contract liabilities: deferred revenue $ — $ 2 $ — $ 2 Contract liabilities: accrued liabilities (includes contract assets) 434 2,338 (2,199 ) 573 Total $ 434 $ 2,340 $ (2,199 ) $ 575
Disaggregation of Revenue [Table Text Block]	Year Ended December 31, 2021 2020 2019 Revenue recognized in the period from: Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied $ 573 $ 434 $ 1,473 New activities in the period: Performance obligations satisfied 7,848 9,500 5,126 $ 8,421 $ 9,934 $ 6,599

Note 18 - Income Taxes (Tables)

Note 18 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	Year Ended December 31, 2021 2020 2019 United States $ (5,824 ) $ (11,034 ) $ (9,652 ) International — — — $ (5,824 ) $ (11,034 ) $ (9,652 )
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Year Ended December 31, 2021 2020 2019 Current Federal $ — $ — $ — State — 5 6 Other — — — Total current tax expense — 5 6 Deferred Federal — — — State — — — Other — — — Total deferred tax expense — — — Income tax provision $ — $ 5 $ 6
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Year Ended December 31, 2021 2020 Deferred tax assets: Net operating losses $ 33,455 $ 31,115 Stock options 884 790 Research and development credits 641 641 Accruals 306 267 Operating lease liabilities 19 109 Property and equipment 10 2 Other deferred tax assets 376 81 Total deferred tax assets 35,691 33,005 Deferred tax liabilities: Operating lease right-of-use assets (19 ) (108 ) Total deferred tax liabilities (19 ) (108 ) Valuation allowance (35,672 ) (32,897 ) Net deferred taxes $ — $ —
Summary of Operating Loss Carryforwards and Tax Credit Carryforwards [Table Text Block]	Expiration Amount Years Net operating losses, federal (Post December 31, 2017) $ 30,989 Does Not Expire Net operating losses, federal (Pre January 1, 2018) $ 94,886 Beginning in 2024 Net operating losses, state $ 106,784 Beginning in 2028 Tax credits, federal $ 1,321 Beginning in 2026 Tax credits, state $ 325 Indefinite
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	Year Ended December 31, 2021 2020 Unrecognized benefit - beginning of period $ 974 $ 974 Change during the period — — Unrecognized benefit - end of period $ 974 $ 974
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 2021 2020 2019 Statutory rate 21.0 % 21.0 % 21.0 % State tax 11.2 % 3.2 % 3.1 % Change in valuation allowance (47.7 %) (11.7 %) (23.0 %) Warrant/equity expenses 16.7 % (10.3 %) 1.7 % Stock-based compensation expense (1.1 %) (4.0 %) (3.7 %) Other (0.1 %) 1.7 % (0.3 %) Impact of 162m — % — % 1.1 % Total 0.0 % (0.1 %) (0.1 %)

Note 19 - Related Party Trans_2

Note 19 - Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Related Party Transactions [Table Text Block]	Year Ended December 31, 2021 2020 2019 Related party revenue: NeutroPhase $ 368 $ 524 $ 209 Licensing — — 41 Total related party revenue $ 368 $ 524 $ 250 Cost of goods sold NeutroPhase $ 325 $ 384 $ 176 Licensing — — — Total related party expenses $ 325 $ 384 $ 176 Year Ended December 31, 2021 2020 2019 Commissions to China Kington related to: OP Private Placement $ — $ — $ — June 2019 Private Placement — — 144 August 2019 Private Placement — — 162 Exercise of June 2019 Warrants — 41 — Exercise of 2019 Foreign Warrants — 160 — Promissory Note to Pioneer Pharma (Hong Kong) Company Ltd. — — 20 Total commissions to China Kington — 201 326 Board Director Bob Wu consulting fee — 50 83 Total related party expenses $ — $ 251 $ 409

Note 21 - Segment Reporting (Ta

Note 21 - Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Year Ended Percentage December 31, 2021 of Total Revenue Optical & Wound Care $ 7,834 93 % Skincare 587 7 % Total revenue $ 8,421 100 % Year Ended Percentage December 31, 2021 of Total Gross Margin Optical &Wound Care $ 5,336 95 % Skincare 309 5 % Total gross margin $ 5,645 100 %

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounts Receivable, Allowance for Credit Loss, Ending Balance	$ 0	$ 0
Inventory Valuation Reserves, Ending Balance	641	236
Goodwill and Intangible Asset Impairment, Total	0	$ 0
Payment for Product Supply Period (Day)		30 days
Advertising Expense	$ 3,200	$ 1,700	$ 500
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	7 years
Computer Equipment and Software [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Computer Equipment and Software [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	7 years

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Components of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash and cash equivalents	$ 7,504	$ 11,952
Restricted cash included in other assets	475	475
Total cash, cash equivalents, and restricted cash in the consolidated statements of cash flows	$ 7,979	$ 12,427	$ 7,412	$ 3,658

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Total sales, net	$ 8,421	$ 9,934	$ 6,599
Avenova Spray [Member]
Total sales, net	6,844	5,974	6,347
DERMAdoctor [Member]
Total sales, net	587	0	0
KN95 Masks [Member]
Total sales, net	0	3,124	0
NeutroPhase [Member]
Total sales, net	368	524	209
Other Products [member]
Total sales, net	598	294	0
Total Product Revenue [Member]
Total sales, net	8,397	9,916	6,556
Product and Service, Other [Member]
Total sales, net	$ 24	$ 18	$ 43

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Revenues and Accounts Receivable From Major Distribution Partners and Customers (Details) - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue from Contract with Customer Benchmark [Member] | Avenova via Amazon [Member]
Distribution or collaboration partners	59.00%	50.00%	15.00%
Revenue from Contract with Customer Benchmark [Member] | Distributor A [Member]
Distribution or collaboration partners			17.00%
Revenue from Contract with Customer Benchmark [Member] | Distributor B [Member]
Distribution or collaboration partners			16.00%
Revenue from Contract with Customer Benchmark [Member] | Distributor C [Member]
Distribution or collaboration partners			15.00%
Accounts Receivable [Member] | Major US Retailer [Member]
Distribution or collaboration partners	33.00%
Accounts Receivable [Member] | Distributor A [Member]
Distribution or collaboration partners	13.00%	18.00%
Accounts Receivable [Member] | Distributor B [Member]
Distribution or collaboration partners		14.00%
Accounts Receivable [Member] | Distributor C [Member]
Distribution or collaboration partners	11.00%	14.00%
Accounts Receivable [Member] | Chongqing Pioneer Pharma Holdings Limited [Member]
Distribution or collaboration partners		16.00%
Accounts Receivable [Member] | Amazon [Member]
Distribution or collaboration partners		11.00%

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Goodwill and Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Nov. 05, 2021
Intangible Assets, Including Goodwill, Fair Value Disclosure	$ 9,788	$ 9,788
Finite-Lived Intangible Assets [Member] | Customer Relationships [Member]
Customer relationships	$ 290
Useful life (Year)	7 years
Finite-Lived Intangible Assets [Member] | Trade Secrets [Member]
Customer relationships	$ 2,890
Useful life (Year)	9 years
Indefinite-lived Intangible Assets [Member] | Trade Names [Member]
Trade names	$ 2,080
Goodwill [Member]
Goodwill	$ 4,528

Note 2 - Summary of Significa_8

Note 2 - Summary of Significant Accounting Policies - Calculation of Basic and Diluted EPS (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Net loss	$ (5,824)	$ (11,039)	$ (9,658)
Less: Preferred deemed dividend	735	0	800
Less: Retained earnings reduction related to warrants down round feature triggered	0	0	29
Net loss attributable to common stockholders, basic and diluted	$ (6,559)	$ (11,039)	$ (10,487)
Weighted average shares outstanding, basic and diluted (in shares)	43,657	35,076	21,641
Net loss per share, basic and diluted (in dollars per share)	$ (150)	$ (310)	$ (480)

Note 2 - Summary of Significa_9

Note 2 - Summary of Significant Accounting Policies - Outstanding Stock Options and Stock Warrants Excluded From the Diluted Net Loss Per Share Computation (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Anti-dilutive securities (in shares)	11,531	10,232	10,771
Share-based Payment Arrangement, Option [Member]
Anti-dilutive securities (in shares)	4,449	3,165	2,183
Warrant [Member]
Anti-dilutive securities (in shares)	7,082	7,067	8,588

Note 3 - Business Combination_2

Note 3 - Business Combination (Details Textual) $ in Millions	Nov. 05, 2021USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)
Number of Operating Segments		2
General and Administrative Expense [Member]
Business Combination, Acquisition Related Costs		$ 1.2	$ 1.2
DERMAdoctor [Member]
Payments to Acquire Businesses, Gross	$ 12
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 3

Note 3 - Business Combination -

Note 3 - Business Combination - Pro Forma Financial Information (Details) - DERMAdoctor [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue	$ 12,767	$ 18,170
Net Profit (Loss)	$ (4,918)	$ (11,647)

Note 3 - Business Combination_3

Note 3 - Business Combination - Purchase Price Allocation of Estimated Fair Values of Identifiable Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Nov. 05, 2021	Dec. 31, 2021	Dec. 31, 2020
Goodwill		$ 4,528	$ 0
DERMAdoctor [Member]
Cash and cash equivalents	$ 12
Accounts receivable, net of allowance for doubtful accounts	1,015
Inventory, net of allowance	2,369
Prepaid expenses and other current assets	150
Property and equipment, net	62
Other intangible assets	54
Accounts payable	(200)
Accrued liabilities	(683)
Total net assets	2,779
Intangible assets	5,260
Net assets acquired	8,039
Purchased consideration	12,561
Goodwill	4,528
DERMAdoctor [Member] | Customer Relationships [Member]
Intangible assets	290
DERMAdoctor [Member] | Trade Secrets [Member]
Intangible assets	2,890
DERMAdoctor [Member] | Trade Names [Member]
Intangible assets	$ 2,080

Note 3 - Business Combination_4

Note 3 - Business Combination - Fair Value of Identifiable Intangible Assets Acquired (Details) - USD ($) $ in Thousands	Nov. 05, 2021	Dec. 31, 2021
Intangible Assets, Including Goodwill, Fair Value Disclosure	$ 9,788	$ 9,788
Finite-Lived Intangible Assets [Member] | Customer Relationships [Member]
Customer relationships		$ 290
Useful life (Year)		7 years
Finite-Lived Intangible Assets [Member] | Customer Relationships [Member] | DERMAdoctor [Member]
Customer relationships	$ 290
Useful life (Year)	7 years
Finite-Lived Intangible Assets [Member] | Trade Secrets [Member]
Customer relationships		$ 2,890
Useful life (Year)		9 years
Finite-Lived Intangible Assets [Member] | Trade Secrets [Member] | DERMAdoctor [Member]
Customer relationships	$ 2,890
Useful life (Year)	9 years
Indefinite-lived Intangible Assets [Member] | Trade Names [Member]
Trade names		$ 2,080
Indefinite-lived Intangible Assets [Member] | DERMAdoctor [Member] | Trade Names [Member]
Trade names	$ 2,080
Goodwill [Member]
Goodwill		$ 4,528
Goodwill [Member] | DERMAdoctor [Member]
Goodwill	$ 4,528

Note 4 - Fair Value Measureme_3

Note 4 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Fair Value Adjustment of Warrants	$ (4,615)	$ 5,216	$ (749)
The 2019 Domestic & Foreign Warrants [Member]
Fair Value Adjustment of Warrants	9,100
The 2019 Ladenburg Warrants [Member]
Fair Value Adjustment of Warrants	$ 200

Note 4 - Fair Value Measureme_4

Note 4 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Restricted cash held as a certificate of deposit	$ 324	$ 324
Deposit held as a certificate of deposit	151	151
Total assets	475	475
Warrant liability	9,558
Contingent earnout liability	561
Total liabilities	10,119
Fair Value, Inputs, Level 1 [Member]
Restricted cash held as a certificate of deposit	324	324
Deposit held as a certificate of deposit	151	151
Total assets	475	475
Warrant liability	0
Contingent earnout liability	0
Total liabilities	0
Fair Value, Inputs, Level 2 [Member]
Restricted cash held as a certificate of deposit	0	0
Deposit held as a certificate of deposit	0	0
Total assets	0	0
Warrant liability	0
Contingent earnout liability	0
Total liabilities	0
Fair Value, Inputs, Level 3 [Member]
Restricted cash held as a certificate of deposit	0	0
Deposit held as a certificate of deposit	0	0
Total assets	0	$ 0
Warrant liability	9,558
Contingent earnout liability	561
Total liabilities	$ 10,119

Note 4 - Fair Value Measureme_5

Note 4 - Fair Value Measurements - Fair Value of Warrant Liability (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair value of warrant liability at December 31, 2020	$ 0	$ 4,092
Fair value of warrant liability at December 31, 2021	9,558	0
Issuance Elimination of embedded derivative liability upon settlement of convertible noteWarrants		(1)
Warrant Liability [Member]
Fair value of 2021 Warrants issued	14,172
Decrease in fair value of 2021 Warrants	$ (4,614)	5,238
Embedded Derivative Liability [Member]
Decrease in fair value of 2021 Warrants		(2)
Expiration of Warrants [Member]
Decrease in fair value of 2021 Warrants		(22)
The 2019 Preferred Warrant and 2019 Common Warrant Liability [Member]
Fair value of warrant liability transferred to equity		(9,108)
The 2019 Ladenburg Warrants [Member]
Fair value of warrant liability transferred to equity		$ (197)

Note 5 - Prepaid Expenses and_3

Note 5 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Prepaid inventory	$ 368	$ 0
Prepaid insurance	138	165
Prepaid consulting services	68	0
Prepaid sales rebates	19	144
Prepaid security deposit for lease	0	65
Prepaid dues and subscription	18	53
Prepaid rent	14	0
Prepaid patents	9	47
Other	144	102
Total prepaid expenses and other current assets	$ 778	$ 576

Note 6 - Inventory - Summary of

Note 6 - Inventory - Summary of Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Raw materials and supplies	$ 1,179	$ 159
Finished goods	2,682	685
Less: Reserve for excess and obsolete inventory	(641)	(236)
Total inventory, net	$ 3,220	$ 608

Note 7 - Property and Equipme_3

Note 7 - Property and Equipment (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Depreciation, Total	$ 59
Depreciation, Depletion and Amortization, Total	119	$ 51	$ 65
Impairment, Long-Lived Asset, Held-for-Use, Total	$ 12	$ 10

Note 7 - Property and Equipme_4

Note 7 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property and equipment, at cost	$ 834	$ 686
Less: accumulated depreciation and amortization	(641)	(602)
Total property and equipment, net	193	84
Office and Laboratory Equipment [Member]
Property and equipment, at cost	20	20
Furniture and Fixtures [Member]
Property and equipment, at cost	157	157
Computer Equipment and Software [Member]
Property and equipment, at cost	464	365
Production Equipment [Member]
Property and equipment, at cost	114	65
Leasehold Improvements [Member]
Property and equipment, at cost	$ 79	$ 79

Note 8 - Accrued Liabilities -

Note 8 - Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Contract liabilities (see Note 16)	$ 1,289	$ 730
Employee payroll and benefits	443	632
Sublease security deposit	0	198
Inventory purchases	0	181
Consulting service	0	98
Other	360	276
Total accrued liabilities	$ 2,092	$ 2,115

Note 9 - Line of Credit (Detail

Note 9 - Line of Credit (Details Textual) - Line of Credit [Member] - Bank Midwest [Member] - USD ($) $ in Thousands	Dec. 31, 2021	Jan. 06, 2022	Nov. 06, 2021
Line of Credit Facility, Maximum Borrowing Capacity			$ 500
Long-term Line of Credit, Total	$ 105
Debt Instrument, Base Floor	5.00%
Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	1.50%
Subsequent Event [Member]
Long-term Line of Credit, Total		$ 0

Note 10 - Commitments and Con_3

Note 10 - Commitments and Contingencies (Details Textual) $ in Thousands	Jan. 22, 2021shares	Dec. 31, 2021ft²shares	Dec. 31, 2020USD ($)	Apr. 16, 2020
Class of Warrant or Right, Issued During Period (in shares)		15,000
TLF Bio Innovation, Related Party Warrants [Member]
Class of Warrant or Right, Issued During Period (in shares)	15,000
Warrants in Connection with Microprofit Agreement [Member]
Class of Warrant or Right, Number of Securities Callable by Warrants or Rights Represented as Percentage of Company’s Outstanding Common Stock				12.00%
Riverside, Missouri [Member]
Area of Real Estate Property (Square Foot) | ft²		19,136
Sublease Agreement [Member]
Operating Lease, Gain (Loss) | $			$ 54
KBSIII Towers [Member]
Lessee, Operating Lease, Renewal Term (Year)		5 years

Note 10 - Commitments and Con_4

Note 10 - Commitments and Contingencies - Lease Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating lease cost	$ 418	$ 826
Sublease income	0	(421)
Net lease cost	418	405
Operational cash flow used for operating leases	$ 475	$ 927
Weighted-average remaining lease term (in years) (Year)	2 years 6 months	1 year 2 months 12 days
Weighted-average discount rate	6.00%	12.00%

Note 10 - Commitments and Con_5

Note 10 - Commitments and Contingencies - Schedule of Future Lease Payments (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
2022	$ 216
2023	129
2024	130
Thereafter	0
Total future minimum lease payments	475
Less imputed interest	(29)
Total	446
Operating lease liability	200	$ 416
Operating lease liability- non-current	246	$ 87
Total	$ 446

Note 11 - Related Party Note _2

Note 11 - Related Party Note Payable (Details Textual) - USD ($) $ in Thousands	May 14, 2020	Feb. 27, 2019	Dec. 31, 2021	Dec. 31, 2020
Pioneer Hong Kong [Member] | Promissory Note [Member]
Debt Instrument, Face Amount		$ 1,000
Debt Instrument, Periodic Payment, Interest	$ 300	200
Repayments of Long-term Debt, Total	$ 1,000
Debt Issuance Costs, Net, Total		$ 20
Interest Expense, Total			$ 0	$ 75
China Kington [Member]
Brokering Fee, Percent		2.00%
Consulting Agreement, Term (Year)		1 year
Consulting Agreement, Amount		$ 100

Note 12 - Convertible Note (Det

Note 12 - Convertible Note (Details Textual) - USD ($) $ in Thousands	Mar. 26, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Proceeds from Convertible Debt		$ 0	$ 0	$ 2,000
Iliad Research and Trading, L.P. [Member] | Secured Convertible Promissory Note [member]
Debt Instrument, Face Amount	$ 2,200
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Proceeds from Convertible Debt	$ 2,000
Debt Instrument, Original Issue Discount	200
Debt Instrument, Fee Amount	15
Deferred Finance Costs Excluding Transaction Fees	$ 200
Debt Instrument, Interest Rate During Period			20.00%
Interest Expense, Debt, Total			$ 200

Note 13 - Warrant Liability (De

Note 13 - Warrant Liability (Details Textual) - USD ($) $ in Thousands	Oct. 27, 2020	Mar. 06, 2020	Mar. 31, 2020	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Nov. 02, 2021	Sep. 30, 2019	Aug. 13, 2019
Class of Warrant or Right, Outstanding (in shares)				7,067,000		7,082,000	7,067,000
Proceeds from Warrant Exercises					$ 6,800	$ 0	$ 7,098	$ 67
The July 2011 Warrants [Member]
Class of Warrant or Right, Expired During Period (in shares)		35,107	35,107
Class of Warrant or Right, Outstanding (in shares)				0		0	0
October 2015 Warrants [Member]
Class of Warrant or Right, Expired During Period (in shares)	15,320				15,320
Class of Warrant or Right, Outstanding (in shares)				0		0	0
Class of Warrant or Right, Exercised During Period (in shares)				22,680	22,680
Proceeds from Warrant Exercises				$ 5	$ 5
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity				$ 12
The 2019 Domestic Warrants [Member]
Class of Warrant or Right, Outstanding (in shares)				0		0	0
Warrants and Rights Outstanding				$ 4,900			$ 4,900			$ 3,100	$ 3,100
Warrants and Rights Outstanding				4,900			4,900			$ 3,100	3,100
The 2019 Foreign Warrants [Member]
Warrants and Rights Outstanding				4,200			4,200				2,000
Warrants and Rights Outstanding				4,200			4,200				2,000
The 2019 Ladenburg Warrants [Member]
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity						$ 0	9,108	$ 553
Warrants and Rights Outstanding				200			200				100
Warrants and Rights Outstanding				$ 200			$ 200				$ 100
The 2021 Warrants [Member]
Warrants and Rights Outstanding						9,600			$ 14,200
Warrants and Rights Outstanding						$ 9,600			$ 14,200

Note 13 - Warrant Liability - T

Note 13 - Warrant Liability - The Key Assumptions Used to Value the Warrants (Details)	Dec. 31, 2021	Nov. 02, 2021	Dec. 31, 2019
Warrants assumptions	0.25	0.38
Measurement Input, Price Volatility [Member] | The 2019 Domestic Warrants [Member]
Warrants assumptions			1.78
Measurement Input, Price Volatility [Member] | The 2019 Foreign Warrants [Member]
Warrants assumptions			1.78
Measurement Input, Price Volatility [Member] | The 2019 Ladenburg Warrants [Member]
Warrants assumptions			1.86
Measurement Input, Price Volatility [Member] | The 2021 Warrants [Member]
Warrants assumptions	0.87	0.849
Measurement Input, Expected Term [Member] | The 2019 Domestic Warrants [Member]
Warrants assumptions			4.57
Measurement Input, Expected Term [Member] | The 2019 Foreign Warrants [Member]
Warrants assumptions			4.57
Measurement Input, Expected Term [Member] | The 2019 Ladenburg Warrants [Member]
Warrants assumptions			4.05
Measurement Input, Expected Term [Member] | The 2021 Warrants [Member]
Warrants assumptions	6	6.2
Measurement Input, Risk Free Interest Rate [Member] | The 2019 Domestic Warrants [Member]
Warrants assumptions			0.0025
Measurement Input, Risk Free Interest Rate [Member] | The 2019 Foreign Warrants [Member]
Warrants assumptions			0.0027
Measurement Input, Risk Free Interest Rate [Member] | The 2019 Ladenburg Warrants [Member]
Warrants assumptions			0.0022
Measurement Input, Risk Free Interest Rate [Member] | The 2021 Warrants [Member]
Warrants assumptions	0.0131	0.0129
Measurement Input, Expected Dividend Rate [Member] | The 2019 Domestic Warrants [Member]
Warrants assumptions			0
Measurement Input, Expected Dividend Rate [Member] | The 2019 Foreign Warrants [Member]
Warrants assumptions			0
Measurement Input, Expected Dividend Rate [Member] | The 2019 Ladenburg Warrants [Member]
Warrants assumptions			0
Measurement Input, Expected Dividend Rate [Member] | The 2021 Warrants [Member]
Warrants assumptions	0	0
Measurement Input, Share Price [Member] | The 2019 Domestic Warrants [Member]
Warrants assumptions			1.18
Measurement Input, Share Price [Member] | The 2019 Foreign Warrants [Member]
Warrants assumptions			1.54
Measurement Input, Share Price [Member] | The 2019 Ladenburg Warrants [Member]
Warrants assumptions			1.17

Note 14 - Stockholders' Equit_2

Note 14 - Stockholders' Equity (Details Textual) $ / shares in Units, $ in Thousands	Oct. 29, 2021USD ($)$ / sharesshares	Oct. 27, 2020shares	Mar. 06, 2020shares	Mar. 31, 2020shares	Dec. 31, 2021USD ($)$ / sharesshares	Jun. 30, 2021USD ($)shares	Dec. 31, 2020USD ($)$ / sharesshares	Sep. 30, 2020USD ($)$ / sharesshares	Jun. 30, 2020USD ($)shares	Mar. 31, 2020USD ($)shares	Sep. 30, 2019USD ($)$ / sharesshares	Jun. 30, 2019USD ($)$ / sharesshares	Dec. 31, 2015$ / sharesshares	Mar. 31, 2015$ / sharesshares	Sep. 30, 2011$ / sharesshares	Dec. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)	Jan. 31, 2022shares	Nov. 02, 2021USD ($)	Jan. 15, 2021$ / sharesshares	Aug. 13, 2019USD ($)	May 31, 2019$ / shares	Feb. 29, 2016$ / shares	Oct. 31, 2015$ / shares
Preferred Stock, Shares Authorized (in shares)					5,000,000		5,000,000									5,000,000	5,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares					$ 1.63		$ 1.63									$ 1.63	$ 1.63
Common Stock, Shares Authorized (in shares)					100,000,000		75,000,000									100,000,000	75,000,000
Adjustments to Additional Paid in Capital, Beneficial Conversion Feature Upon Issuance of Stock | $																$ 735
Payments of Stock Issuance Costs | $								$ 200
Preferred Stock, Shares Outstanding, Ending Balance (in shares)					14,000		0									14,000	0
Proceeds from Issuance of Common Stock | $																$ 1,776	$ 5,220	$ 6,698
Class of Warrant or Right, Issued During Period (in shares)																15,000
Class of Warrant or Right, Outstanding (in shares)					7,082,000		7,067,000									7,082,000	7,067,000
Proceeds from Warrant Exercises | $								6,800								$ 0	$ 7,098	$ 67
China Kington [Member]
Payments of Stock Issuance Costs | $								$ 200
Ladenburg Thalmann and Co. Inc. [Member]
Payments of Stock Issuance Costs | $											$ 300
Private Placement, Commission Percentage											6.00%
Payments of Stock Issuance Costs, Reimbursement of Expenses | $											$ 60
Payments of Stock Issuance Costs, Other | $											$ 300
Subsequent Event [Member]
Common Stock, Shares Authorized (in shares)																			150,000,000
The 2021 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	37,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 0.53
Warrants and Rights Outstanding | $					$ 9,600											$ 9,600				$ 14,200
The July 2011 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)															139,520
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares															$ 33.25								$ 0.2061	$ 1.81	$ 5
Class of Warrant or Right, Issued During Period (in shares)															139,520
Class of Warrant or Right, Expired During Period (in shares)			35,107	35,107
Class of Warrant or Right, Outstanding (in shares)					0		0									0	0
March 2015 Short-term and Long-term Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)														649,133
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																							0.2061	1.81	$ 5
Class of Warrant or Right, Issued During Period (in shares)														649,133
Class of Warrant or Right, Expired During Period (in shares)										7,419
Class of Warrant or Right, Outstanding (in shares)					0											0
Class of Warrant or Right, Exercised During Period (in shares)										70,000
Proceeds from Warrant Exercises | $										$ 14
March 2015 Warrants [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares														$ 15
March 2015 Warrants [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares														$ 16.25
March 2015 Warrants Expiring March 6, 2020 [Member]
Class of Warrant or Right, Issued During Period (in shares)														278,200
March 2015 Warrants Expiring June 6, 2015 [Member]
Class of Warrant or Right, Issued During Period (in shares)														370,933
October 2015 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)													442,802
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares													$ 5										$ 0.2061	$ 1.81
Class of Warrant or Right, Issued During Period (in shares)													442,802
Class of Warrant or Right, Expired During Period (in shares)		15,320						15,320
Class of Warrant or Right, Outstanding (in shares)					0		0									0	0
Class of Warrant or Right, Exercised During Period (in shares)							22,680	22,680
Proceeds from Warrant Exercises | $							$ 5	$ 5
The June 2019 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)												1,371,427
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares												$ 0.87
Class of Warrant or Right, Issued During Period (in shares)												1,371,427
Class of Warrant or Right, Expired During Period (in shares)									571,428
Class of Warrant or Right, Outstanding (in shares)					0											0
Class of Warrant or Right, Exercised During Period (in shares)									571,428	228,571
Proceeds from Warrant Exercises | $									$ 497	$ 199
Class of Warrant or Right Call Feature Minimum Stock Price (in dollars per share) | $ / shares												$ 1
The June 2019 Warrants [Member] | China Kington [Member]
Payments for Commission, Exercise of Warrants | $									$ 29	$ 12
Exercise of Warrants, Commission, Percent				6.00%					6.00%	6.00%
The 2019 Domestic Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)											4,198,566
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares											$ 1.15
Warrants and Rights Outstanding | $							$ 4,900				$ 3,100						$ 4,900					$ 3,100
Payments of Stock Issuance Costs Allocated to Warrants | $											200
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | $											$ 300
Class of Warrant or Right, Issued During Period (in shares)											4,198,566
Class of Warrant or Right, Outstanding (in shares)					0		0									0	0
The 2019 Ladenburg Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)											167,942
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares								$ 0.99			$ 1.25
Warrants and Rights Outstanding | $							$ 200										$ 200					100
Payments of Stock Issuance Costs Allocated to Warrants | $											$ 59
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | $											$ 65
Class of Warrant or Right, Issued During Period (in shares)											167,942
The 2019 Foreign Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares								$ 0.99
Warrants and Rights Outstanding | $							$ 4,200										$ 4,200					$ 2,000
Exercise of Warrants, Commission, Percent								6.00%
New Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								6,898,566
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares								$ 1.65
Warrants and Rights Outstanding, Term (Year)								5 years 6 months
TLF Bio Innovation 2021 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																					15,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																					$ 0.6718
Warrants and Rights Outstanding, Term (Year)																					5 years
Conversion of Series B Preferred Stock to Common Stock [Member]
Adjustments to Additional Paid in Capital, Beneficial Conversion Feature Upon Issuance of Stock | $					$ 700
The 2021 Private Placement Program [Member]
Payments of Stock Issuance Costs | $																$ 1,700
Payments of Stock Issuance Costs Allocated to Warrants | $																1,600
The 2021 Private Placement Program [Member] | Conversion of Series B Preferred Stock to Common Stock [Member]
Preferred Stock, Convertible, Shares Issuable (in shares)	37,500,000
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares	$ 0.40
Preferred Stock, Convertible, Conversion Ratio	2,500
Maximum Percentage of Common Stock Outstanding	19.99%
Preferred Stock, Convertible, Maximum Common Stock Shares Converted (in shares)	8,984,178
ATM Program [Member]
Stock Issued During Period, Shares, New Issues (in shares)						2,672,000			5,836,792
Payments of Stock Issuance Costs | $						$ 100			$ 400
Proceeds from Issuance of Common Stock | $						$ 1,800			$ 5,600
Private Placement [Member]
Payments of Stock Issuance Costs | $												$ 27
Private Placement [Member] | Three Accredited Investors [Member]
Stock Issued During Period, Shares, New Issues (in shares)												1,371,427
Issuance of Stock and Warrants During the Period, Value | $												$ 2,400
Private Placement [Member] | Xiao Rui Liu [Member]
Issuance of Stock and Warrants During the Period, Value | $												1,000
Private Placement [Member] | Hai Dong Pang [Member]
Issuance of Stock and Warrants During the Period, Value | $												400
Private Placement [Member] | Ping Huang [Member]
Issuance of Stock and Warrants During the Period, Value | $												1,000
Private Placement [Member] | China Kington [Member]
Payments of Stock Issuance Costs | $												$ 100
Private Placement, Commission Percentage												6.00%
August 2019 Common Stock Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)											4,198,566
Payments of Stock Issuance Costs | $											$ 500
Proceeds from Issuance of Stock and Warrants | $											$ 4,200
Series B Preferred Stock [Member] | The 2021 Private Placement Program [Member]
Stock Issued During Period, Shares, New Issues (in shares)	15,000
Preferred Stock, Convertible, Shares Issuable (in shares)	37,500,000
Proceeds from Issuance of Preferred Stock and Preference Stock | $	$ 14,900
Preferred Stock, Purchase Price (in dollars per share) | $ / shares	$ 1,000
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | $																$ 100

Note 14 - Stockholders' Equit_3

Note 14 - Stockholders' Equity - Outstanding Warrants (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Outstanding warrants (in shares) | shares	7,067
Outstanding warrants, weighted-average exercise price (in dollars per share) | $ / shares	$ 1.63
Warrants granted (in shares) | shares	15
Warrants granted, weighted average exercise price (in dollars per share) | $ / shares	$ 0.67
Warrants expired (in shares) | shares	0
Warrants expired, weighted average exercise price (in dollars per share) | $ / shares	$ 0
Outstanding warrants (in shares) | shares	7,082
Outstanding warrants, weighted-average exercise price (in dollars per share) | $ / shares	$ 1.63

Note 15 - Equity-based Compen_3

Note 15 - Equity-based Compensation (Details Textual) - USD ($) $ in Thousands	Jan. 15, 2021	Nov. 17, 2020	Jul. 31, 2021	Jul. 31, 2020	Mar. 31, 2017	Oct. 31, 2007	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jul. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)								0	20,000	83,000
Proceeds from Stock Options Exercised								$ 0	$ 7	$ 189
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value									0	0
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total								$ 1,200
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)								2 years 3 months 14 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)								516,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)								1,528,000
Share-based Payment Arrangement, Expense								$ 933	$ 532	$ 486
Share-based Payment Arrangement, Nonemployee [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)								0	400,000	0
Share-based Payment Arrangement, Expense								$ 240	$ 64	$ 37
Share-based Payment Arrangement, Nonemployee [Member] | Partner and Senior Vice President of China Kington [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		300,000							300,000
Employees and Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)								516,000	1,158,000	145,000
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense								$ 700	$ 500	$ 400
Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Nonemployee [Member] | Partner and Senior Vice President of China Kington [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)		1 year
Share-based Payment Arrangement, Option [Member] | Messrs. Ma [Member]
Share-based Payment Arrangement, Expense								14
Share-based Payment Arrangement, Option [Member] | Mr. Liu [Member]
Share-based Payment Arrangement, Expense								7
Share-based Payment Arrangement, Option [Member] | Mr. Sieczkarek [Member]
Share-based Payment Arrangement, Expense								60
Share-based Payment Arrangement, Option [Member] | Mr. Todd Zavodnick [Member]
Share-based Payment Arrangement, Expense								24
Share-based Payment Arrangement, Option [Member] | Ms. Gail Maderis [Member]
Share-based Payment Arrangement, Expense								36
Share-based Payment Arrangement, Option [Member] | Mr. Xiaopei Wang [Member]
Share-based Payment Arrangement, Expense								$ 17
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)								1,200,000
Restricted Stock Units (RSUs) [Member] | Employees and Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)									160,000	0
Restricted Stock [Member] | Share-based Payment Arrangement, Nonemployee [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)								0
Restricted Stock [Member] | Mr. Mark Sieczkarek [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			328,359	192,983						168,000
Share-based Payment Arrangement, Expense											$ 400
Restricted Stock [Member] | Mr. Mark Sieczkarek [Member] | Share-based Payment Arrangement, Tranche One [Member]
Share-based Payment Arrangement, Expense			$ 200
Restricted Stock [Member] | Mr. Mark Sieczkarek [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Share-based Payment Arrangement, Expense			$ 200
Restricted Stock [Member] | Ms. Moon and Ms. Xiao [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)							36,000
The 2007 Omnibus Incentive Plan [Member] | Maximum [Member] | Incentive Stock Options (ISOs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)						10 years
The 2017 Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)					2,318,486
Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase in Shares Authorized, Percentage of Outstanding Common Stock					4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)	1,671,303
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)								1,842,993
The 2017 Omnibus Incentive Plan [Member] | Incentive Stock Options (ISOs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percentage of Stock Owned by Shareholder, Minimum					10.00%
The 2017 Omnibus Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)					4 years
The 2017 Omnibus Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)					10 years
The 2017 Omnibus Incentive Plan [Member] | Maximum [Member] | Incentive Stock Options (ISOs) [Member] | Shareholder of More Than 10% [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)					5 years
The 2017 Omnibus Incentive Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent					100.00%
The 2017 Omnibus Incentive Plan [Member] | Minimum [Member] | Incentive Stock Options (ISOs) [Member] | Shareholder of More Than 10% [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent					110.00%

Note 15 - Equity-based Compen_4

Note 15 - Equity-based Compensation - Stock Options Outstanding (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Outstanding awards (in shares)	3,165,000
Outstanding, weighted-average exercise price (in dollars per share)	$ 2.05
Outstanding, weighted-average remaining contractual life (Year)	7 years 7 months 6 days	7 years 7 months 6 days
Outstanding, aggregate intrinsic value	$ 460	$ 189
Options granted (in shares)	516,000
Options granted, weighted-average exercise price (in dollars per share)	$ 0.66
Restricted stock units granted (in shares)	1,528,000
Options forfeited/cancelled (in shares)	(272,000)
Options forfeited/cancelled, weighted-average exercise price (in dollars per share)	$ 2.35
Outstanding awards (in shares)	4,449,000	3,165,000
Outstanding, weighted-average exercise price (in dollars per share)	$ 1.39	$ 2.05
Vested and expected to vest (in shares)	4,125,000
Vested and expected to vest, weighted-average exercise price (in dollars per share)	$ 1.46
Vested and expected to vest, weighted-average remaining contractual life (Year)	7 years 6 months
Vested and expected to vest, aggregate intrinsic value	$ 406
Vested (in shares)	2,150,000
Vested, weighted-average exercise price (in dollars per share)	$ 2.42
Vested, weighted-average remaining contractual life (Year)	5 years 4 months 24 days
Vested, aggregate intrinsic value	$ 8
Exercisable (in shares)	2,150,000
Exercisable, weighted-average exercise price (in dollars per share)	$ 2.42
Exercisable, weighted-average remaining contractual life (Year)	5 years 10 months 24 days
Exercisable, aggregate intrinsic value	$ 8
Restricted Stock Units (RSUs) [Member]
Restricted stock units granted (in shares)	1,200,000
Restricted stock units vested (in shares)	(488,000)

Note 15 - Equity-based Compen_5

Note 15 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Employees and Directors (Details) - Employees and Directors [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Expected price volatility	164.00%	161.00%	112.00%
Expected term (Year)	6 years 2 months 8 days	6 years 5 months 12 days	6 years 1 month 20 days
Risk-free interest rate	1.05%	0.45%	1.99%
Dividend yield	0.00%	0.00%	0.00%
Weighted-average fair value of options granted during the period (in dollars per share)	$ 0.64	$ 0.94	$ 0.31

Note 15 - Equity-based Compen_6

Note 15 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Non-employees (Details) - Nonemployees [Member]	12 Months Ended
	Dec. 31, 2020$ / shares
Expected price volatility	162.00%
Expected term (in years) (Year)	6 years 4 months 2 days
Risk-free interest rate	0.50%
Dividend yield	0.00%
Weighted-average fair value of options granted during the period (in dollars per share)	$ 0.73

Note 15 - Equity-based Compen_7

Note 15 - Equity-based Compensation - Summary of Stock-based Compensation Expense Included in Results of Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Stock-based compensation expense	$ 933	$ 532	$ 486
Research and Development Expense [Member]
Stock-based compensation expense	10	23	42
Selling and Marketing Expense [Member]
Stock-based compensation expense	129	85	93
General and Administrative Expense [Member]
Stock-based compensation expense	$ 794	$ 424	$ 351

Note 16 - License, Collaborat_3

Note 16 - License, Collaboration and Distribution Agreements (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue from Contract with Customer, Including Assessed Tax	$ 8,421	$ 9,934	$ 6,599
Avenova Direct [Member]
Revenue from Contract with Customer, Including Assessed Tax	5,100	3,300	1,000
McKesson Corporation [Member] | Avenova Product [Member]
Contract with Customer, Liability, Revenue Recognized	600	1,700	$ 4,600
McKesson Corporation [Member] | Avenova Product [Member] | Accounts Payable and Accrued Liabilities [Member]
Contract with Customer, Liability, Total	900	700
McKesson Corporation [Member] | Avenova Product [Member] | Prepaid Expenses and Other Current Assets [Member]
Contract with Customer, Rebate Liability, Current	$ 19	$ 144

Note 16 - License, Collaborat_4

Note 16 - License, Collaboration and Distribution Agreements - Changes in Assets and Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Contract Liabilities: Deferred Revenue, Balance at beginning of the period	$ 2	$ 0
Contract Liabilities: Deferred Revenue, additions	176	2
Contract Liabilities: Deferred Revenue, deductions	(124)	0
Contract Liabilities: Deferred Revenue, Balance at the end of the period	54	2
Contract Liabilities: Accrued Liabilities,Balance at beginning of the period	573	434
Contract Liabilities: Accrued Liabilities, additions	1,851	2,338
Contract Liabilities: Accrued Liabilities, deductions	(1,154)	(2,199)
Contract Liabilities: Accrued Liabilities, Balance at the end of the period	1,270	573
Contract Liabilities, Balance at beginning of the period	575	434
Contract Liabilities, additions	2,027	2,340
Contract Liabilities, deductions	(1,278)	(2,199)
Contract Liabilities, Balance at the end of the period	$ 1,324	$ 575

Note 16 - License, Collaborat_5

Note 16 - License, Collaboration and Distribution Agreements - Total Revenues (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Total sales, net	$ 8,421	$ 9,934	$ 6,599
Transferred over Time [Member]
Total sales, net	573	434	1,473
Transferred at Point in Time [Member]
Total sales, net	$ 7,848	$ 9,500	$ 5,126

Note 17 - Employee Benefit Pl_2

Note 17 - Employee Benefit Plan (Details Textual) - USD ($) $ in Thousands	Jan. 01, 2022	Dec. 31, 2021	Dec. 31, 2020
The 401(k) Plan [Member]
Defined Contribution Plan, Employer Discretionary Contribution Amount		$ 0	$ 0
The 401K Plan Contribution Level One [Member] | Forecast [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	100.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	3.00%
The 401K Plan Contribution Level Two [Member] | Forecast [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	50.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	2.00%

Note 18 - Income Taxes (Details

Note 18 - Income Taxes (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 2.8	$ 1.3	$ 2.2
Domestic Tax Authority [Member]
Open Tax Year	2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
State and Local Jurisdiction [Member]
Open Tax Year	2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021

Note 18 - Income Taxes - Loss B

Note 18 - Income Taxes - Loss Before Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
United States	$ (5,824)	$ (11,034)	$ (9,652)
International	0	0	0
Loss before provision for income taxes	$ (5,824)	$ (11,034)	$ (9,652)

Note 18 - Income Taxes - Federa

Note 18 - Income Taxes - Federal and State Income Tax Provisions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current
Federal	$ 0	$ 0	$ 0
State	0	5	6
Other	0	0	0
Total current tax expense	0	5	6
Deferred
Federal	0	0	0
State	0	0	0
Other	0	0	0
Total deferred tax expense	0	0	0
Income tax provision	$ 0	$ 5	$ 6

Note 18 - Income Taxes - Summar

Note 18 - Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Net operating losses	$ 33,455	$ 31,115
Stock options	884	790
Research and development credits	641	641
Accruals	306	267
Operating lease liabilities	19	109
Property and equipment	10	2
Other deferred tax assets	376	81
Total deferred tax assets	35,691	33,005
Operating lease right-of-use assets	(19)	(108)
Total deferred tax liabilities	(19)	(108)
Valuation allowance	(35,672)	(32,897)
Net deferred taxes	$ 0	$ 0

Note 18 - Income Taxes - Summ_2

Note 18 - Income Taxes - Summary of Net operating Loss and Tax Credit Carryforwards (Details) $ in Thousands	Dec. 31, 2021USD ($)
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Not Subject to Expiration [Member]
Net operating losses	$ 30,989
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Expiration Years 2024 - 2037 [Member]
Net operating losses	94,886
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Expiration Years 2026 - 2035 [Member]
Tax credits	1,321
State and Local Jurisdiction [Member] | Not Subject to Expiration [Member]
Tax credits	325
State and Local Jurisdiction [Member] | Expiration Years 2028 - 2037 [Member]
Net operating losses	$ 106,784

Note 18 - Income Taxes - Unreco

Note 18 - Income Taxes - Unrecognized Tax Benefit (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Unrecognized benefit - beginning of period	$ 974	$ 974
Change during the period	0	0
Unrecognized benefit - end of period	$ 974	$ 974

Note 18 - Income Taxes - Effect

Note 18 - Income Taxes - Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statutory rate	21.00%	21.00%	21.00%
State tax	11.20%	3.20%	3.10%
Change in valuation allowance	(47.70%)	(11.70%)	(23.00%)
Warrant/equity expenses	16.70%	(10.30%)	1.70%
Stock-based compensation expense	(1.10%)	(4.00%)	(3.70%)
Other	(0.10%)	1.70%	(0.30%)
Impact of 162m	0.00%	0.00%	1.10%
Total	0.00%	(0.10%)	(0.10%)

Note 19 - Related Party Trans_3

Note 19 - Related Party Transactions (Details Textual) - USD ($) $ in Thousands	Nov. 17, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounts Receivable, Related Parties		$ 100	$ 200
Accounts Payable, Related Parties		$ 0	8
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		516,000
Share-based Payment Arrangement, Expense		$ 933	532	$ 486
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense		$ 700	$ 500	$ 400
Share-based Payment Arrangement, Nonemployee [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		0	400,000	0
Share-based Payment Arrangement, Expense		$ 240	$ 64	$ 37
Share-based Payment Arrangement, Nonemployee [Member] | Eric Wu [Member]
Share-based Payment Arrangement, Expense		$ 152	$ 15
Partner and Senior Vice President of China Kington [Member] | Share-based Payment Arrangement, Nonemployee [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	300,000		300,000
Partner and Senior Vice President of China Kington [Member] | Share-based Payment Arrangement, Nonemployee [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	1 year

Note 19 - Related Party Trans_4

Note 19 - Related Party Transactions - Related Party Revenue, Cost of Goods Sold, and Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Total related party revenue	$ 368	$ 524	$ 250
Cost of goods sold	325	384	176
Total related party expenses	0	251	409
Director Bob Wu [Member]
Total related party expenses	0	50	83
China Kington [Member]
Total related party expenses	0	201	326
China Kington [Member] | The OP Warrants [Member]
Total related party expenses	0	0	0
China Kington [Member] | The June 2019 Warrants [Member]
Total related party expenses	0	0	144
China Kington [Member] | The August 2019 Warrants [Member]
Total related party expenses	0	0	162
China Kington [Member] | Broker Fee for the Exercise of the June 2019 Warrants [Member]
Total related party expenses	0	41	0
China Kington [Member] | The 2019 Foreign Warrants [Member]
Total related party expenses	0	160	0
China Kington [Member] | Promissory Note [Member]
Total related party expenses	0	0	20
NeutroPhase [Member]
Total related party revenue	368	524	209
Cost of goods sold	325	384	176
Licensing [Member]
Total related party revenue	0	0	41
Cost of goods sold	$ 0	$ 0	$ 0

Note 20 - Paycheck Protection_2

Note 20 - Paycheck Protection Program (Details Textual) - USD ($) $ in Thousands	May 24, 2021	May 06, 2020	Dec. 31, 2021	Dec. 31, 2020
Paycheck Protection Program CARES Act [Member]
Other Nonoperating Income			$ 0	$ 900
Paycheck Protection Program CARES Act [Member] | Wells Fargo Bank [Member]
Proceeds from Issuance of Long-term Debt, Total		$ 900
Gain (Loss) on Extinguishment of Debt, Total	$ 900

Note 21 - Segment Reporting (De

Note 21 - Segment Reporting (Details Textual)	12 Months Ended
	Dec. 31, 2021
Number of Reportable Segments	2

Note 21 - Segment Reporting - F

Note 21 - Segment Reporting - Financial Information by Segment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue from Contract with Customer, Including Assessed Tax	$ 8,421	$ 9,934	$ 6,599
Total of Revenue	100.00%
Gross margin	$ 5,645	$ 5,964	$ 4,861
Total of gross margin	100.00%
Optical and Wound Care [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 7,834
Total of Revenue	93.00%
Gross margin	$ 5,336
Total of gross margin	95.00%
Skincare [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 587
Total of Revenue	7.00%
Gross margin	$ 309
Total of gross margin	5.00%

Note 22 - Subsequent Events (De

Note 22 - Subsequent Events (Details Textual) - shares	Jan. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Common Stock, Shares Authorized (in shares)		100,000,000	75,000,000
Subsequent Event [Member]
Common Stock, Shares Authorized (in shares)	150,000,000